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ABSTRACT 
 
 
 Regulatory T (Treg) cells suppress CD4+ T cell responses during homeostasis and 
inflammation to prevent autoimmunity and other immune disorders. Although the 
transcriptional and epigenetic programs impacting Treg cell function have been 
extensively studied, the signaling and metabolic pathways underlying Treg stability and 
function are not fully understood. In this study, we determined the role of the phosphatase 
PTEN in Treg cells. We found that specific depletion of PTEN in Treg cells results in 
excessive TH1 and T follicular helper cells (TFH) responses, associated with elevated 
germinal center (GC) B cells and spontaneous development of autoimmune and 
lymphoproliferative disease in vivo. Interestingly, the exaggerated TFH and GC responses 
and autoimmune symptoms are suppressed when IFN-γ expression is abrogated in mice 
containing Pten-deficient Treg cells. Thus, the uncontrolled TH1-mediated inflammation 
in these mice drives aberrant TFH responses and autoimmune and lymphoproliferative 
disease. Mechanistically, we linked PTEN to mTORC2-mediated control of 
transcriptional and metabolic programs that enforce Treg cell stability and function. 
Consistent with this notion, deletion of Rictor, the obligate component for mTORC2, 
restores Treg cell function and stability in the absence of Pten. Similarly, partially 
restoring the activity of Foxo1, a downstream transcription factor negatively regulated by 
mTORC2 signaling, also largely rectified the defects of PTEN-deficient Treg cells. 
Together, these results establish that Treg cells rely on the PTEN-mTORC2-Foxo1 axis 
to maintain their stability and suppressive activity in controlling TH1 and TFH cell 
responses. 
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CHAPTER 1.    INTRODUCTION 
 
 
Overview 
 
Regulatory T (Treg) cells, identified as the Foxp3+ subset of CD4+ T cells, 
maintain tolerance to self-antigens and prevent autoimmune diseases (Josefowicz et al., 
2012; Tang and Bluestone, 2008). Continuous T cell receptor (TCR) activation is 
important for Treg cell function (Levine et al., 2014). TCR signaling activates the 
phosphoinositide 3-kinase (PI3K), AKT, and the mechanistic target of rapamycin 
(mTOR) pathways. The strength and duration of PI3K, AKT, and mTOR signaling 
modulates Foxp3 expression to control Treg cell development or differentiation (Chi, 
2012). Further, the level of mTOR signaling also affects the suppressive function of Treg 
cells (Park et al., 2013; Wei et al., 2016; Zeng et al., 2013). Phosphatase and tensin 
homolog (PTEN, encoded by the Pten gene) is a lipid phosphatase that directly opposes 
PI3K signaling by dephosphorylating phosphatidylinositol (3,4,5)-trisphosphate (PIP3) to 
generate phosphatidylinositol (3,4)-bisphosphate (PIP2). However, molecular pathways 
mediated by PTEN and its role specifically in Treg cells remain to be established. 
Therefore, the main goals of our study were the following:  
 
1. Investigate the mechanism by which PTEN signaling controls the homeostasis 
and functions of Treg cells.  
2. Identify signaling pathways and target genes involved in PTEN-mediated 
regulation of Treg cells.  
 
 
T Cell Development, Homeostasis, and Differentiation  
 
T cells are white blood cells that develop in the thymus from bone marrow-
derived hematopoietic stem cells (HSCs). Specifically, HSCs differentiate into multi-
potent progenitors capable of further differentiating into common lymphoid progenitors 
that give rise to T cells, B cells, and natural killer cells. Once in the thymus, lymphoid 
progenitors lose alternative lineage potential and commit to the T cell fate (Germain, 
2002; Yang et al., 2010). The thymic microenvironment provides unique signals to T cell 
precursors, causing changes in transcriptional signatures that promote the expression of 
functional, antigen-specific TCRs. Ultimately, these precursors undergo TCR positive 
and negative selection and finally, they leave thymus to become mature CD4+ or CD8+ T 
cells. 
 
Upon egress from thymus, T cells are maintained in a quiescent state. Quiescent T 
cells are smaller in cell size and have lower metabolic rates than activated T cells, which 
is discussed in greater detail below. Further, they are maintained in the G0 phase of the 
cell cycle. Because TCR repertoire diversity is important for recognition of many 
pathogens, quiescence may preserve energy to limit the size of the naïve T cell pool 
(Yang and Chi, 2012). Several transcription factors, including Krüpple-like factor 2 
(KLF2) and Forkhead box protein P1 (Foxp1), are essential for the maintenance of T cell 
quiescence (Buckley et al., 2001; Feng et al., 2010). The signaling molecules regulating T 
 2 
cell quiescence have also been extensively studied and are discussed in other reviews 
(Hamilton and Jameson, 2012; Hua and Thompson, 2001; Yang and Chi, 2012). Below, 
we briefly discuss how the mTOR pathway regulates T cell quiescence. 
 
Upon receiving the appropriate activating stimuli, naïve T cells proliferate and 
differentiate into effector T cells. These differentiated effector populations are termed 
CD4+ T helper (TH) cells and CD8+ cytotoxic T lymphocytes (CTLs). Three activating 
signals are required to drive TH and CTL differentiation. Signal 1 is generated by 
interaction of TCR with the cognate peptide presented in the context of the major 
histocompatibility complex (MHC) molecule (Banchereau and Steinman, 1998). The 
second signal is co-stimulation, achieved when CD28 on the T cell engages CD80 and/or 
CD86 on the antigen-presenting cell (APC) (Reis e Sousa, 2006). Finally, signal 3 is 
cytokine stimulation provided by APCs that function to orchestrate effector T cell 
differentiation (Curtsinger and Mescher, 2010). CD4+ cells are involved in serving other 
immune cells, such as B cells for antibody production and activation of macrophages to 
promote clearance of infectious agents. CD8+ T cells, on the other hand, are directly 
involved in killing infected host cells by releasing perforins and granzymes.  
 
 
Differentiation of Conventional CD4+ T Cells 
 
Naïve CD4+ T cells circulate between the blood and secondary lymphoid organs. 
Upon receiving cognate antigen and co-stimulatory signals from APCs, naïve CD4+ T 
cells are activated, proliferate, and can further differentiate into effector CD4+ T cells. 
The major CD4+ T helper subsets are T helper (TH) 1, TH2, TH17, and T follicular helper 
(TFH) cells (Figure 1-1). Cellular function, transcription factors and signature cytokine 
profiles characterize these TH subsets. The signals and transcription factors driving TH 
subset differentiation are discussed below.  
 
 
TH1 cells 
 
 Early analysis of mouse CD4+ T cell clones established the existence of two 
distinct T cell subsets. The first subset, called TH1 cells, predominantly secretes 
interferon (IFN)-γ; these cells also produce interleukin (IL)-2 and tumor necrosis factor 
alpha (TNF-α) (Mosmann et al., 1986; Zhu et al., 2010). TH1 cells are primarily 
responsible for cell-mediated immunity via the activation of macrophages, neutrophils, 
and natural killer cells; they also aid CTL differentiation. TH1 cells are known to be 
involved in cellular immunity and help eradicate intracellular bacteria; however, 
overexpression of IL-12 causes excessive TH1 responses, leading to inflammation and 
autoimmune diseases, such as type 1 diabetes, in mice and humans (Szelachowska et al., 
1997; Trembleau et al., 1995; Trembleau et al., 1999). TH1 responses are also known to 
be involved in the development of systemic lupus erythematosus (SLE). Elevated IFN-γ 
concentrations are detected in SLE patients (Gerez et al., 1997). In mouse models of SLE, 
IFN-γ is linked to exacerbated disease development, which can be significantly delayed 
using anti-IFN-γ antibody (Jacob et al., 1987). Thus, excessive TH1 responses can play a  
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Figure 1-1. Schematic representation of conventional helper T cell diversity.  
Naïve CD4+ T cells can differentiate into several different types of helper T cell subsets 
depending on cytokines and transcription factors present during activation.  
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detrimental role in autoimmune disease development, but how these responses contribute 
to disease development are not clear. 
 
In addition to TCR and co-stimulatory signals, IFN-γ and IL-12 play important 
roles in helping naïve T cells commit towards TH1 cells. Naïve T cells do not express IL-
12 receptor inducible chain (IL-12Rβ2), which is required for activation of the signaling 
pathway involved in TH1 differentiation. TCR activation induces IL-12Rβ2 expression. 
IL-12Rβ2 expression is further stabilized by IFN-γ, allowing IL-12R signaling to 
progress and ensure TH1 cell differentiation (Szabo et al., 1997). Mechanistically, IL-12R 
signaling is coupled to signal transducer and activator of transcription (STAT) 4 
activation, which in turn promotes T-box transcription factor T-bet (encoded by Tbx21) 
expression (Szabo, Kim et al. 2000; Zhu, Yamane et al. 2010). It has been shown that T-
bet-deficient naïve T cells fail to differentiate into TH1 cells, resulting in enhanced 
susceptibility to Leishmania major and other bacterial infections (Ravindran et al., 2005; 
Sullivan et al., 2005; Szabo et al., 2002). T-bet regulates the expression of IFN-γ (Szabo 
et al., 2000; Zhu et al., 2010). Additionally, T-bet intrinsically suppresses the 
differentiation of other TH subsets, which are discussed below. Future studies will 
determine how the interplay between different T cell subsets influence TH1 responses in 
different disease contexts.  
 
 
TH2 cells  
 
 The second subset identified in early screens of mouse T cell clones was the TH2 
population. TH2 responses are important for clearance of extracellular pathogens and 
parasites, such as helminths and nematodes (Finkelman et al., 1991; Sher and Coffman, 
1992). In addition to producing the signature cytokine IL-4, TH2 cells produce IL-5 and 
IL-13 (Nelms et al., 1999; Zhu et al., 2010). TH2 cells also promote B cell antibody class-
switching to generate IgG and IgE (Coffman et al., 1988; Killar et al., 1987). However, 
TH2-associated cytokines contribute to the induction of asthma and allergy. For instance, 
IL-5 causes airway hyperresponsiveness (AHR) (Cho et al., 2004; Foster et al., 1996). 
Moreover, excessive IL-4 and IL-5 production is linked to hyper-IgE production, 
eosinophil activation, and mast cell growth, which cause tissue injury. IL-13 stimulates 
mucus production, ultimately leading to increased airway obstruction (Danahay et al., 
2002; Maddox and Schwartz, 2002). TH2-associated cytokines, therefore, act via several 
mechanisms to promote asthma and allergic disease pathologies. 
 
IL-4R signaling via STAT6 and the induction of the transcription factor GATA 
binding protein 3 (GATA3) are required for TH2 cell differentiation. GATA3 positively 
regulates and maintains TH2 programming by promoting IL-4 expression, by binding to 
the IL-5 promoter to regulate its expression, and by supporting the continuous production 
of IL-13 (Zhou and Ouyang, 2003; Zhu, 2010). Moreover, TH1 and TH2 differentiation 
programs are antagonistic. Stable GATA3 expression inhibits TH1 differentiation, as it 
blocks expression of IFN-γ (Lazarevic et al., 2013; Zhu et al., 2004). Additionally, IL-4 
antagonizes IL-12Rβ2 expression to block TH1 polarization (Szabo et al., 1997).  
Conversely, it has been implicated that T-bet suppresses IL-4 expression (Szabo et al., 
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2000).  As TH2 cell-derived cytokines also help limit acute and chronic inflammation 
driven by excessive TH1 immune responses, there may be a potential therapeutic role for 
these cells in the treatment of TH1-associated diseases.   
 
 
TH17 cells 
 
In addition to TH1 and TH2 cells, a third major subset of CD4+ TH cells was 
identified. TH17 cells help provide host defense against extracellular bacteria and fungi 
by recruiting neutrophils and macrophages to infected tissues (Laan et al., 1999). IL-17A, 
IL-17F and IL-22 are the signature cytokines produced by TH17 cells (Korn et al., 2009), 
Excessive TH17 cell responses play significant roles in organ-specific autoimmunity. For 
example, excessive IL-17 levels contribute to joint destruction in a collagen-induced 
arthritis mouse model (Lubberts et al., 2002). TH17 responses are also harmful in the 
experimental autoimmune encephalomyelitis (EAE) mouse model of multiple sclerosis 
(MS) (Langrish et al., 2005), the mechanisms of which are discussed more fully below.  
 
The differentiation of TH17 cells requires the transcription factors, retinoic orphan 
receptor (ROR)γt and RORα, which regulate IL-17A and IL-17F production (Korn, 
Bettelli et al. 2009). The expression of RORγt is controlled by the combined actions of 
the cytokines, transforming growth factor (TGF)-β, IL-6 and IL-21. STAT1 signaling 
downstream of IL-6 and IL-21 is critical to support TH17 cell differentiation. Other 
transcription factors also stabilize and promote TH17 programming, including interferon 
regulatory factor 4 (IRF4) and runt-related transcription factor 1 (RUNX1) (Brustle et al., 
2007; Huber et al., 2008; Zhang et al., 2008). The TH1 differentiation program can also 
suppress TH17 differentiation, as T-bet curtails TH17 commitment by inhibiting the 
induction of RUNX1-mediated induction of RORγt (Lazarevic et al., 2013). The TH17 
program is also strongly antagonized by those inducing Foxp3+ T cells in the periphery, 
via mechanisms that involve Foxp3-mediated suppression of RORγt and RORα (Du et 
al., 2008; Ivanov et al., 2006; Zhou et al., 2008). 
 
Compared to the other TH subsets, TH17 cells appear to be less stable. The 
stability of the TH17 lineage is regulated by the cytokine IL-23 (Stritesky et al., 2008). 
IL-23 consists of the p19 and p40 subunits. Mice deficient in p19 and p40 are protected 
from EAE (Cua et al., 2003). Additionally, treatment with anti-p19 and anti-p40 
antibodies reduces EAE severity (Chen et al., 2006). By contrast, IL-23 overexpression 
exacerbates EAE (Langrish, Chen et al. 2005), thereby establishing a critical role for IL-
23 in TH17-mediated disease pathologies (Awasthi et al., 2009; Thakker et al., 2007). The 
ability of IL-23 to promote disease may be linked to pathogenic TH17 cell differentiation. 
In adoptive transfer systems, TH17 cells polarized in the presence of TGF-β1 and IL-6 
cannot drive EAE development; however, exposure to IL-23 drives autocrine TGF-β3 
signaling that promotes TH17 pathogenicity (Lee et al., 2012). Destabilization of the TH17 
lineage can also occur under conditions when TGF-β signaling dominates over TH17-
polarizing proinflammatory cytokines (e.g. IL-6), resulting in the differentiation of 
Foxp3+ T cells over TH17 cells (Ivanov et al., 2006).    
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TFH cells 
 
TFH cells are a specialized subset of CD4+ T cells that migrate to B cell follicles 
and provide signals to B cells, promoting germinal center reactions in secondary 
lymphoid organs such as spleen, lymph node and Peyer’s patches (Crotty, 2011; Vinuesa 
et al., 2016). Germinal centers (GCs) are important sites for antibody affinity maturation 
mediated by B cell clonal expansion and somatic hypermutation. They also serve as sites 
for memory and plasma B cell differentiation. The differentiation of TFH cells from naïve 
CD4+ T cells requires interactions with dendritic cells (DCs) in T cell areas and with B 
cells in B cell follicles and germinal centers, as discussed below. The lineage specific 
transcription factors for TFH programming are B-cell lymphoma 6 protein (Bcl6) and 
achaete-scute family bHLH transcription factor 2 (Ascl2) (Johnston et al., 2009; Liu et 
al., 2014; Nurieva et al., 2009; Yu et al., 2009). TFH cells also are characterized by the 
expression of chemokine receptor, CXCR5, co-stimulatory/inhibitory molecules ICOS 
and PD-1, and various effector molecules CD154 (also called CD40L), OX40, BTLA and 
CD84 (Crotty, 2011; Ma et al., 2012; Vinuesa et al., 2016). IL-21 is the primary cytokine 
essential for differentiation of TFH cells (Crotty, 2011; Vinuesa et al., 2016). 
 
Uncontrolled, excessive TFH responses lead to the development of autoimmune 
diseases. SLE is among these diseases and is characterized by the production of 
autoantibodies (Craft, 2012; Linterman et al., 2009). Additionally, increased TFH 
frequencies have been seen in patients infected with human immunodeficiency virus 
(HIV) (Cubas et al., 2013; Lindqvist et al., 2012; Perreau et al., 2013). Various cancers, 
such as angioimmunoblastic T-cell lymphoma (AITL) and peripheral T-cell lymphoma-
not otherwise specified (PCTL-NOS), also have increased TFH responses (de Leval et al., 
2007; Dorfman et al., 2006; Dupuis et al., 2006; Huang et al., 2009; Ma and Deenick, 
2014). Studies are currently aimed at understanding how TFH responses are exacerbated 
in these various diseases.  
 
TFH cell differentiation requires interactions with both dendritic and B cells. Like 
other TH subsets, TFH priming is initiated when naïve T cells receive TCR and co-
stimulatory signals from DCs. During priming, ICOS-ICOSL interactions and IL-6R 
signaling are essential to support commitment into early-TFH cells (Xu et al., 2013). 
These pre-TFH upregulate CXCR5 expression and downregulate CCR7 expression, 
allowing them to migrate to the T-B cell border and B cell follicle of secondary lymphoid 
tissues. Liu et al. has shown the transcription factor Ascl2 helps in TFH programming by 
upregulating CXCR5 and CXCR4 expression, and downregulating CCR7 and PSGL1 
expression. As such, Ascl2 expression helps initiate T cell migration to B cell follicles 
and suppresses TH1, TH2 and TH17 differentiation (Liu et al., 2014). Further, IL-6 
signaling induces B-cell lymphoma 6 protein (Bcl6) expression in pre-TFH cells, and this 
transcription factor is essential only for TFH differentiation among the TH subsets 
(Johnston et al., 2009; Nurieva et al., 2009; Yu et al., 2009). Additionally, Bcl6 represses 
the expression of cytokines and transcription factors essential for TH1, TH2 and TH17 
differentiation. In support of this view, transducing CD4+ T cells with a Bcl6-encoding 
retrovirus reduced T-bet and GATA3 expression in TH1 and TH2 polarizing conditions, 
respectively (Yu et al., 2009). Furthermore, overexpression of Bcl6 also reduces IFN-γ 
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and IL-17 production, cytokines associated with the TH1 and TH17 programs, respectively 
(Yu et al., 2009).  
 
The second stage of TFH differentiation begins when pre-TFH interact with B cells 
localized in T-B cell border or B cell follicle (Crotty, 2014; Vinuesa et al., 2016). B cell-
pre-TFH interactions can promote differentiation of short-lived plasmablasts, or these 
interactions can promote maturation of the GC reactions. GC-associated, mature TFH cells 
express higher levels of CXCR5 and Bcl6 than pre-TFH or other activated TH subsets. To 
promote mature TFH differentiation, B cells provide antigen and co-stimulatory signals 
via ICOS to pre-TFH cells to further drive TFH differentiation. Signaling lymphocyte 
activation molecule-associated protein (SAP) promotes TFH and B cells adhesion (Qi et 
al., 2008), which is an important process for the differentiation of TFH cells, GC B cells, 
memory B cells and plasma cells (Hu et al., 2013). Mechanistically, SAP binds SLAM 
family member 6 (SLAMF6), a molecule necessary for TFH function (Kageyama et al., 
2012), and the SAP-SLAM interaction drives IL-4 production by TFH cells. Then, IL-4 
and IL-21 derived from TFH promotes GC B cell survival and proliferation (Crotty, 2011; 
Vinuesa et al., 2016). IL-21 expressed by TFH and GC B cells also helps in plasma cell 
differentiation (Ozaki et al., 2004). In addition to being GC resident cells, mature TFH 
also have the capacity to exit the GC, where they can migrate to other B cell follicles or 
recirculate as a small population within the bloodstream (Shulman et al., 2013). These 
processes have been summarized in Figure 1-2. 
 
 
Treg Cells 
 
 
Foxp3 is the master transcription factor of Treg cells  
 
In a seminal study by Sakaguchi and colleagues, the presence of a suppressive 
CD4+ T cell subset expressing high levels of CD25 (IL-2 receptor α chain) was identified 
(Sakaguchi et al., 1995). These cells appeared to be distinct from effector T cells also 
expressing CD25, as their antigen-driven proliferation was less than conventional CD4+ T 
cells (Hayashi et al., 2004; Thornton and Shevach, 1998). In experimental systems, the 
CD4+CD25+ T cells were found to suppress autoreactive T cells. Further, depletion of 
CD4+CD25+ T cells promoted organ-specific autoimmune disease, which was averted by 
adoptive transfer of CD4+CD25+ cells. These suppressive T cells are now known as Treg 
cells, and they play a central role in the regulation of the immune responses. These 
responses include the anti-tumor immunity, autoimmunity, allergic responses, graft-vs-
host disease, and pathogen-induced immune responses (Josefowicz et al., 2012; 
Sakaguchi, 2005; Tang and Bluestone, 2008).  
 
The forkhead/winged helix protein Foxp3 functions as a master regulator of Treg 
cell differentiation and is preferentially expressed in CD4+CD25+ T cells in both the 
thymus and spleen (Ohkura and Sakaguchi, 2010). The suppressive activity of Treg cells 
requires continuous expression of Foxp3 (Williams and Rudensky, 2007).  
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Figure 1-2. Multiple signals and differentiation stages are involved in TFH and 
germinal center B cell development. 
Different inducing factors are necessary for different stages of TFH cell differentiation, 
which ultimately help germinal center B cells to produce plasma or memory B cells. 
Reprinted with permission. Craft, J.E. (2012). Follicular helper T cells in immunity and 
systemic autoimmunity. Nature reviews. Rheumatology 8, 337-347. 
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FOXP3 mutations in humans cause a severe multi-organ autoimmune and 
inflammatory disorder known as immune dysregulation, polyendocrinopathy, 
enteropathy, X-linked (IPEX) syndrome (Bennett and Ochs, 2001). Mutating Foxp3 in 
mice also results in X-linked lymphoproliferative disease known as scurfy, which is 
attributed to loss of T cell tolerance (Hori et al., 2003).  
 
 Studies have indicated forkhead box O (Foxo) family transcription factors are 
essential for regulating the expression of Foxp3 and thereby promoting Treg cell 
programming (Harada et al., 2010; Kerdiles et al., 2010; Ouyang et al., 2009; Ouyang et 
al., 2010; Ouyang et al., 2012). Using T cell specific deletion of Foxo1 and Foxo3, 
Ouyang et al. showed that binding of Foxo1 and Foxo3 to the promoter region of Foxp3 
regulates Foxp3 expression (Ouyang et al., 2010). Furthermore, Treg-specific deletion of 
Foxo1 causes an inflammatory disease (Ouyang et al., 2012). Regulation of these Foxo 
factors is tightly controlled by the serine/threonine kinase, AKT (Calnan and Brunet, 
2008; Merkenschlager and von Boehmer, 2010). Specifically, AKT-dependent 
phosphorylation of Foxo proteins sequesters these proteins in the cytoplasm, preventing 
their nuclear functions (Calnan and Brunet, 2008). Interestingly, the balance of Foxo 
signaling is a critical determinant of Treg cell function, since mutating the AKT 
phosphorylation sites of Foxo1 and thereby driving constitutive Foxo1 function in Treg 
cells also drives tissue inflammation (Luo et al., 2016). 
 
 
Stability of Treg cells 
  
A fundamental issue in immunology is the interplay between effector and 
regulatory T cell responses. CD4+Foxp3+ Treg cells regulate inflammatory responses and 
play a central role in protecting tissues from damage. Several pathways have been 
proposed for Treg cell-mediated control of effector T cell responses, including but not 
limited to deprivation of IL-2, secretion of inhibitory cytokines, and modulation of DC 
function via cytotoxic T-lymphocyte antigen-4 (CTLA-4) (Sakaguchi et al., 2009; 
Vignali et al., 2008). The involvement of a particular mechanism may be context-
dependent and may dominate in certain situations.  
 
As noted above, Foxp3 is a crucial transcription factor for Treg cell development 
and function. However, recent work has suggested 10-15% of Treg cells may lose Foxp3 
expression in certain contexts, resulting in death or instability, the latter forming ex-Treg 
cells (Komatsu et al., 2009; Zhou et al., 2009a). These ex-Treg cells no longer express 
high levels of Treg cell markers (e.g. CD25, glucocorticoid-induced TNFR-related 
protein (GITR), CTLA-4 and are unable to suppress effector T cell proliferation in vitro 
(Zhou et al., 2009a). This instability appears to be restricted largely to the 
CD25lowFoxp3+ Treg cell population, as this population has been reported to acquire 
effector TH cell-like functions (Komatsu et al., 2009). For example, Treg cells can 
produce IFN-γ under TH1-polarizing conditions (Dominguez-Villar et al., 2011; Wei et 
al., 2009), and these TH1-effector phenotype Treg cells have reduced immunosuppressive 
function during an immune response to infection (Oldenhove et al., 2009). However, the 
functional consequences of IFN-γ production by Treg cells are still unclear. Studies have 
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suggested that IFN-γ production by allogeneic Foxp3+ Treg cells may be beneficial in 
preventing experimental graft-versus-host disease (Koenecke et al., 2012), while others 
have termed these IFN-γ producing cells as ex-Treg cells that enhance inflammation and 
thereby may contribute to autoimmunity (Zhou et al., 2009b). Defining the mechanisms 
involved in limiting or enhancing Treg cell stability is crucial to understanding immune 
system regulation, functional diversity and fate maintenance of Treg cells. Targeting 
these newly discovered mechanisms could provide novel therapeutic applications for 
disease intervention. 
 
 
Heterogeneity of the Foxp3+ Treg cell population 
 
Similar to conventional CD4+ T cells, Treg cells are classified into different 
specialized subsets based upon their site of development or expression of surface 
molecules. Treg cells arise from the thymus (tTreg cells) or are induced in the periphery 
from naïve CD4+ T cells (pTreg cells). In vivo interactions with self- and non-self 
antigens lead to the differentiation of tTreg cells and pTreg cells, respectively (Dhamne et 
al., 2013; Josefowicz et al., 2012). Naïve T cells can also be polarized into Treg cells in 
vitro (iTreg) in the presence of TGF-β and IL-2. These subsets are discussed in greater 
detail below. 
 
tTreg cells 
 
tTreg cells differentiate from Foxp3+CD4+ T cell precursors found in the thymus 
and comprise 5-10% of peripheral CD4+ T cells. tTreg cells are essential for guarding 
against systemic and tissue-specific autoimmunity. In line with this idea, multi-organ 
autoimmunity is evident in mice that have undergone neonatal thymectomies (Nishizuka 
and Sakakura, 1969). This phenotype is due to the loss of CD4+CD25+ T cells (Asano et 
al., 1996), and the development of autoimmunity is inhibited upon transfer of CD4+, 
CD4+CD8- or CD25+ T cells (Asano et al., 1996; Fowell and Mason, 1993; Sakaguchi et 
al., 1982).  
 
Several signals control tTreg cell differentiation, and these signals appear to be 
derived from the thymic medulla (Cowan, Parnell et al. 2013). TCR recognition of MHC 
class II-bound peptides is essential for the development of tTreg cells, as CD4+Foxp3+ 
Treg cells do not develop in the thymus of MHC-II-deficient mice (Fontenot et al., 2005). 
CD28 co-stimulation is also essential in tTreg cell differentiation, because tTreg cell 
numbers are decreased in CD28, CD80 and CD86 deficient mice (Salomon et al., 2000; 
Tai et al., 2005; Zhou et al., 2009). IL-2 is also necessary for the development of tTreg 
cells, as IL2R-/- mice failed to generate tTreg cells (Cheng et al., 2013; Cowan et al., 
2013). Additional signals in the periphery, including continuous exposure to self-
antigens, IL-2 and TGF-β, are necessary for maintaining stability and function of tTreg 
cells (Li et al., 2006; Marie et al., 2005; Marie et al., 2006). Importantly, tTreg cells 
express similar phenotypic markers as pTreg cells, such as CTLA-4, GITR and OX40, 
but Helios and neuropilin-1 have been suggested as tTreg-specific markers (Dhamne et 
al., 2013). Furthermore, epigenetics studies have shown differences in the modifications 
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of 5'-C-phosphate-G-3' (CpG) in the Treg-specific demethylated regions (TSDRs) of the 
Foxp3 locus between tTreg cells and iTreg cells (Kim et al., 2012; Polansky et al., 2010). 
Specifically, the TSDRs in the Foxp3 locus of tTreg cells are mostly demethylated, 
whereas iTreg cells have predominately-methylated regions (Floess et al., 2007; Lal and 
Bromberg, 2009; Lal et al., 2009; McClymont et al., 2011). 
 
pTreg and iTreg cells 
 
While tTreg cells are major regulators of immune tolerance to self-antigens, 
pTreg cells are believed to dampen inflammatory responses to non-self antigens (Dhamne 
et al., 2013). For instance, pTreg cells are important for controlling inflammation at 
mucosal surfaces (Yadav et al., 2013). It has been reported that pTreg cells are induced in 
vivo under low antigenic conditions (Apostolou and von Boehmer, 2004; Kretschmer et 
al., 2005; Thorstenson and Khoruts, 2001; Weiss et al., 2012). Similar to tTreg cells, 
pTreg cells express canonical markers such as CTLA-4, GITR and CD103. The lack of 
specific markers for pTreg cells has limited in vivo analyses of mechanisms driving their 
differentiation; so, most studies have analyzed the signals driving iTreg cell 
differentiation. IL-2 and TGF-β are required for iTreg cell differentiation from naive 
CD4+ T cells (Davidson et al., 2007; Shevach et al., 2008). Further, Foxp3 expression, 
survival and suppressive function of iTreg cells are maintained by TGF-β (Nakamura et 
al., 2001). Interestingly, iTreg cells have unstable expression of Foxp3 and express a 
different gene signature than in vivo Treg cells (Floess et al., 2007). iTreg cells are not as 
suppressive and have a more limited transcriptional signature than endogenous Treg cells 
(Chen et al., 2003; Fantini et al., 2004; Hill et al., 2007; Wan and Flavell, 2005). Future 
studies will advance our understanding of similarities and differences between these Treg 
cell subsets. 
 
 
T follicular regulatory cells 
 
T follicular regulatory (TFR) cells are a GC-resident Treg cell subset that shares 
phenotypic features of both tTreg cells and TFH cells. This Treg cell subset expresses 
CTLA-4, GITR, Bcl6, ICOS, PD-1 and CXCR5, but are functionally distinct from 
conventional populations. Evidence shows TFR cells originate from tTreg cell precursors 
(Chung et al., 2011; Crotty, 2011; Linterman et al., 2011; Vinuesa et al., 2016). Bcl6, 
SAP, and B cell-deficient mice lack the TFR population, while non-TFR Treg cells are 
represented at normal frequencies, convincingly showing that TFR cells are a distinct Treg 
cell subset (Chung et al., 2011; Linterman et al., 2011; Wollenberg et al., 2011).  
 
TFR cells in the GC center play a role in suppressing TFH cell and B cell responses, 
but the mechanisms for suppression functions remains unclear. Recent studies showed 
CTLA-4 regulate TFR cell suppressive function, as the Treg cell-specific deletion of 
CTLA-4 in mice leads to increased GC responses (Sage et al., 2014; Wing et al., 2014). 
This phenotype is at least partially attributed to diminished TFR function (Sage et al., 
2014). Other means of regulating TFH and GC B cells responses by TFR cells might be 
through inhibitory cytokines, such as TGF-β and/or IL-10, as it is known TFH cells are 
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suppressed by TGF-β and antibody production can be altered by IL-10 (Cai et al., 2012; 
McCarron and Marie, 2014). The molecular pathways that orchestrate the generation and 
function of TFR cells and the interplay with other effector cells remain to be elucidated. 
 
 
mTOR Signaling Pathway 
 
 Rapamycin (also known as sirolimus) is an immunosuppressant drug widely used 
to prevent rejection in organ transplantation. The outcomes of studies identifying how 
rapamycin mediated its effects lead to the discovery of target of rapamycin 1 (TOR1) and 
TOR2 in yeast (Cafferkey et al., 1993; Heitman et al., 1991; Kunz et al., 1993). This 
protein is highly conserved across species and is also expressed in mammalian cells 
(Chiu et al., 1994; Sabatini et al., 1994; Sabers et al., 1995). The mammalian mechanistic 
target of rapamycin (mTOR) is a serine-threonine kinase encoded as a single gene. 
mTOR exists in two functionally distinct, multi-protein complexes. mTOR complex 1 
(mTORC1) is comprised of mTOR associated with and defined by the presence of the 
scaffolding protein Raptor, whereas mTORC2 is associated with and defined by the 
scaffolding protein, Rictor (Figure 1-3) (Chi, 2012; Laplante and Sabatini, 2012). 
mTORC1 activity is sensitive to rapamycin inhibition while mTORC2 activity is 
relatively insensitive to rapamycin, as much higher concentrations or long-term 
treatments of rapamycin are required to inhibit mTORC2 activity (Foster and Toschi, 
2009).  
 
 
Regulation of mTOR activity 
 
Immune signals, environmental cues and nutrients are three instructive signals 
that activate mTOR signaling pathway and ultimately shape T cell development and 
function. There are several regulators upstream of mTOR that help integrate essential 
signals, and enhance or inactivate the mTOR activity. One of the key negative regulators 
of mTORC1 function is tuberous sclerosis complex (TSC), a heterodimer consisting of 
TSC1 (also known as hamartin) and TSC2 (also known as tuberin). Following the 
activation of PI3K-AKT pathway by various receptor systems, the TSC complex is 
inactivated, subsequently activating mTORC1 function. TSC functions as a GTPase 
activating protein for Ras homolog enriched in brain (Rheb), which directly binds to 
mTORC1 and has reported roles in driving mTORC1 activity. Rheb needs to be in GTP 
bound state to help activate mTOR kinase activity. However, TSC converts Rheb to its 
inactive GDP bound form and negatively regulates mTOR (Chi, 2012; Laplante and 
Sabatini, 2012) (Figure 1-4). Rheb-deficient T cells have a transient reduction of 
TCR/CD28-induced mTORC1 activity (Delgoffe et al., 2009; Yang et al., 2013). 
Furthermore, disrupting the TSC1/2 complex by deleting TSC1 upregulates mTORC1 
activity (O'Brien et al., 2011; Wu et al., 2011; Yang et al., 2011). However, growth 
factors like insulin activate mTORC1 via TSC-independent mechanisms, such as through 
the phosphorylation and dissociation of proline-rich AKT substrate of 40-kDa (PRAS40) 
from mTORC1. This process inactivates PRAS40 and subsequently activates mTORC1 
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Figure 1-3. Schematic diagram showing associated protein components of two 
mTOR complexes, mTORC1 and mTORC2. 
mTORC1 is comprised of core scaffolding protein mTOR, Raptor, mLST8 and other 
associated components PRAS40 and Deptor. mTORC2 consists of core protein mTOR, 
Rictor, mLST8 and various associated proteins mSIN1, Protor and Deptor. 
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Figure 1-4. mTOR signaling pathway 
A serine/threonine protein kinase mTOR helps integrate multiple upstream signals such 
as immune signals, environmental cues and nutrients, thereby helping regulate crucial 
cell functions downstream such as cell growth, proliferation, survival, protein synthesis 
and transcription. 
Reprinted with permission. Chi, H. (2012). Regulation and function of mTOR signalling 
in T cell fate decisions. Nature reviews. Immunology 12, 325-338. Courtesy of Dr. 
Hongbo Chi. 
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by allowing it to bind to its substrates (Sancak et al., 2007; Vander Haar et al., 2007; 
Wang et al., 2007). Throughout this dissertation, we discuss how upstream inhibitors of 
mTOR function control the functions of T cells and Treg cells.  
 
mTORC1 controls multiple downstream functions, including protein and lipid 
synthesis, autophagy, cell survival and metabolism. Mechanistically, active mTORC1 
promotes translation and protein synthesis by phosphorylating ribosomal protein S6 
kinases and eIF4e-binding protein. mTORC1 helps control lipid synthesis, which is 
essential for cell proliferation, through sterol regulatory element binding protein 1/2 
(SREBP1/2) transcription factors, and stimulates de novo lipid biogenesis through 
peroxisome proliferator-activated receptor γ (PPAR-γ) dependent regulation (Laplante 
and Sabatini, 2012). mTORC1 inhibits autophagy by phosphorylating unc-51-like kinase 
1 (ULK1) (Ganley et al., 2009; Jung et al., 2009). However, there is a complex interplay 
between mTORC1 and autophagy, as a recent study from our lab has shown deletion of 
genes essential in autophagy resulted in upregulation of mTORC1 promoting defective 
Treg cell function (Wei et al., 2016). mTORC1 also orchestrates cellular metabolism by 
activating transcription and translation of hypoxia inducible factor 1α (HIF-1α)  and c-
Myc (Wang et al., 2011; Wei et al., 2016; Yang et al., 2013). Cell cycling and survival 
are also controlled by mTORC1 via positive regulators such as cyclin D1 and c-Myc 
(Gera et al., 2004). Thus, mTORC1 controls many important biological functions. 
 
mTORC2 also plays important roles in cellular biology. mTORC2 is a crucial 
regulator of AKT activity via mechanisms discussed below (Sarbassov et al., 2005). In 
the absence of mTORC2 function (e.g. Rictor deletion), the AKT-dependent inhibitory 
phosphorylation of the Foxo transcription factors is reduced. These transcription factors 
are essential for expression of genes involved in cell survival, metabolism and 
proliferation (Calnan and Brunet, 2008). AKT is also involved in other cellular 
mechanisms, such as cell proliferation and metabolic regulation. Specifically, AKT 
promotes cell proliferation by phosphorylation of cell cycle regulatory protein p27 (Shin 
et al., 2002), and by indirectly inhibiting the tumor suppressor p53 (Vousden and Lane, 
2007). The AKT pathway is also involved in glucose metabolism, as it is known to 
translocate glucose transporters such as Glut1 and Glut4 to the cell surface. This process 
is essential for promoting glucose metabolism, helping in T cell activation and function 
(Bentley et al., 2003; Boxer et al., 2006; Jessen and Goodyear, 2005; Wieman et al., 
2007). Additional downstream targets activated by mTORC2 are protein kinase C (PKC) 
isoforms as well as serum- and glucocorticoid-regulated kinase 1 (SGK1) (Figure 1-4), 
which in turn regulates cytoskeletal dynamics and ion transport, respectively (Chi, 2012; 
Zarogoulidis et al., 2014). Thus, mTORC2 can influence cell survival, proliferation, 
growth, differentiation, and trafficking. 
 
 
mTOR in T helper cell quiescence and differentiation 
 
 In addition to maintaining T cell homeostasis, mTOR actively participates in the 
highly complex process of T cell differentiation (Figure 1-5). mTORC1 and mTORC2  
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Figure 1-5. mTOR signaling controls peripheral T cell fate decisions. 
mTOR signaling pathway is involved in promoting differentiation of effector helper T 
cell subsets, and inhibits the programming of induced regulatory Treg cells. 
Modified with permission. Chapman, N.M., and Chi, H. (2014). mTOR Links 
Environmental Signals to T Cell Fate Decisions. Frontiers in immunology 5, 686. 
Courtesy of Dr. Nicole Chapman and Dr. Hongbo Chi. 
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serve different roles in regulating T cell differentiation and function (Chapman and Chi, 
2014). Quiescent naïve T cells have low metabolic and energy demands, which is 
correlated with low mTORC1 signaling. Tsc1-/- naïve T cells have excessive mTORC1 
activity, which leads to metabolic dysregulation that promotes spontaneous cell growth, 
increased cell size, overt cellular activation, and cell proliferation. (O'Brien et al., 2011; 
Wu et al., 2011; Yang et al., 2011). Increased apoptotic death induced by TCR 
stimulation occurs in Tsc1-/- naïve T cells and is rescued upon anti-apoptotic protein Bcl2 
overexpression (Yang et al., 2011). Thus, mTORC1 activity is restrained to regulate T 
cell homeostasis.  
 
Furthermore, experiments involving mTOR, Rheb, Raptor and Rictor-deficient T 
cells have shown the importance of mTOR signaling pathway in T cell clonal expansion 
(Delgoffe et al., 2009; Yang et al., 2013). Loss of Rheb diminishes TH1 and TH17 
differentiation, but promotes TH2 polarization (Delgoffe et al., 2011). Absence of Raptor-
mTORC1 signaling results in impaired TH1 or TH2 generation (Yang et al., 2013; Zeng et 
al., 2013). In contrast, loss of Rictor-mTORC2 results in defective TH2 but not TH17 
differentiation. The role of mTORC2 in TH1 generation is controversial and requires 
further investigation (Delgoffe et al., 2011; Lee et al., 2010).  
 
mTOR signaling is also involved in the maintenance and differentiation of CD8+ 
T cells (Araki et al., 2009; Li et al., 2011). Briefly, deletion of Tsc1 during the late stages 
of thymocyte development results in altered CD8+ T cell homeostatic proliferation (Wu et 
al., 2011; Yang et al., 2011; Zhang et al., 2012). Loss of Raptor-mTORC1 function 
results in impaired effector CD8+ T cell responses in vivo (Yang et al., 2013). Recently, 
Pollizzi et al. has linked two different complexes of mTOR, mTORC1 and mTORC2 to 
different phases of CD8+ T cell programming. Briefly, Tsc2 deficiency enhances 
mTORC1 activity and is associated with terminal differentiation of effector CD8+ T cells 
and impaired differentiation into memory CD8+ T cells. Additionally, T cell specific 
deletion of Rheb caused inhibition of effector differentiation of CD8+ T cells, while 
Rictor-deficient T cells have heightened memory CD8+ T cell differentiation and 
responses (Pollizzi et al., 2015). Robust memory CD8+ T cell generation in spleen and 
blood upon rapamycin treatment has also been reported, linking mTOR signaling to 
CD8+ T cell programming. (Sowell et al., 2014).  
 
 
mTOR in Treg cell differentiation and function 
 
The presence and magnitude of mTOR signaling also influence Treg cell function. 
We recently found that Raptor-mTORC1 signaling is an essential regulator of metabolic 
programming necessary for Treg cell function (Yang et al., 2013; Zeng et al., 2013). By 
contrast, Treg cell function is largely normal in cells lacking mTORC2 activity (Zeng, 
Yang et al. 2013). Park et al. demonstrated that the mTORC1 signaling threshold 
maintains Treg cell stability and function. Briefly, the absence of Tsc1 in Treg cells 
causes dysregulated immune homeostasis. Tsc1-deficient Treg cells are unstable and 
acquire an effector TH17-like phenotype (Park et al., 2013). These studies highlight the 
critical role of mTORC1 signaling in Treg cell function. However, the inhibition of both 
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mTORC1 and mTORC2 complex is necessary for the generation of iTreg cells (Delgoffe 
et al., 2009; Delgoffe et al., 2011), suggesting that mTOR signaling is a complex 
regulator of Treg cell biology. 
 
Upstream signals modulate mTOR signaling to control Treg cell function. For 
example the sphingosine-1-phosphate receptor 1 (S1PR1)-mTOR axis controls the 
programming of Treg cells in the thymus and periphery, thereby limiting the suppressive 
function of Treg cells in vivo and in vitro (Liu et al., 2009; Liu et al., 2010). Autocrine 
signaling of the hormone leptin modulates Treg cell proliferation via the leptin receptor. 
It has been reported that leptin strongly induces mTORC1 activity in Treg cells. 
Additionally, transient mTORC1 inhibition and loss of either leptin or its receptor 
receptor subsequently promotes anti-CD3/28-induced Treg cell proliferation. 
Interestingly, the expression of leptin and leptin receptor by Treg cells is regulated by 
mTORC1 activation, because short-term rapamycin treatment suppresses their 
expressions. Therefore, the leptin-mTOR pathway dynamically regulates energy 
metabolism essential for Treg cells to control self-tolerance (Procaccini et al., 2010). 
 
 
mTOR and T cell metabolism  
 
Distinct metabolic programs exist throughout different stages of T cell 
development. Quiescent naïve T cells engage oxidative phosphorylation (OXPHOS) or 
fatty acid oxidation (FAO) to generate adenosine triphosphate (ATP) (Fox et al., 2005; 
Pearce and Pearce, 2013; van der Windt and Pearce, 2012; Wang et al., 2011). Activated 
T cells require greater energy demands to rapidly grow and proliferate, which is mediated 
primarily by aerobic glycolysis (MacIver et al., 2013; Vander Heiden et al., 2009). 
Furthermore, TH1, TH2 and TH17 cells rely upon glycolysis, whereas Treg cells engage 
fatty acid oxidation (Michalek et al., 2011a; Zeng and Chi, 2013). Extensive crosstalk 
between metabolic programming and the mTOR signaling pathway is crucial for T cell 
fate decisions (Buck et al., 2015). Briefly, rapamycin treatment in activated T cells blocks 
c-Myc expression as well as glycolytic activity (Shi et al., 2011; Wang et al., 2011). 
Although naïve T cells experience comparatively low metabolic activity, increased 
mTORC1 activity in Tsc1−/− naïve T cells is linked to the upregulation of genes related to 
glucose metabolism (Yang et al., 2011). Upon TCR activation, Tsc2−/− T cells are highly 
glycolytic (Michalek et al., 2011b). Tone of the downstream targets of mTORC1, HIF-
1α, plays a crucial role in glycolysis. Interestingly, HIF-1α−/− mice have increased Treg 
cells, pointing to an inhibitory role for glycolytic metabolism in Treg cell function (Shi et 
al., 2011). Furthermore, a recent study from our lab suggested that dysregulated 
glycolytic activity can impair Treg cell stability (Wei et al., 2016). We further explore the 
link between glycolytic metabolism and Treg cell function in this project. 
 
 
Phosphatase and Tensin Homolog (PTEN) 
 
 The Pten gene was identified in 1997 as a tumor suppressor and is also known as 
Telomerase-Associated Protein 1 (TEP1) and Mutated in Multiple Advanced Cancers 1 
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(MMAC1) (Li and Sun, 1997; Li et al., 1997; Steck et al., 1997). This gene is located in 
long (q) arm of chromosome 10 at position 23.3 and is frequently mutated in a large 
number of human cancers (Chalhoub and Baker, 2009). In humans, germline mutations in 
PTEN are associated with several cancers and developmental disorders. PTEN 
Hamartoma Tumor Syndrome (PHTS) is a spectrum of disorders caused by loss of 
function of PTEN. PHTS includes Cowden syndrome (CS), Bannayan-Riley-Ruvalcaba 
syndrome (BRRS), PTEN-related Proteus syndrome (PS), and Proteus-like syndrome 
(PLS) (Hobert and Eng, 2009). Additionally, heterozygous loss of PTEN function or 
expression is known to cause autoimmune disease and cancers (Salmena et al., 2008; 
Song et al., 2012). Even nearly 20 years after its discovery, most PTEN-related research 
studies have focused on its tumor suppressor functions. Little is known regarding the role 
of PTEN in autoimmune disorders, specifically within Treg cells, which we aim to 
characterize in this project. 
 
 
Structure and regulation of PTEN 
 
PTEN is composed of 403 amino acids and has five distinct functional domains, 
which are the N-terminal region PIP2 binding domain, a phosphatase domain for 
enzymatic activity, a C2 domain for membrane recruitment, a carboxy-terminal tail 
thought to maintain stability and a PDZ-binding domain for protein interactions  
(Figure 1-6) (Georgescu, 2010; Leslie et al., 2008; Song et al., 2012). The function of 
PTEN is regulated through various mechanisms. Epigenetic changes via DNA promoter 
methylation modulate Pten expression at the transcription level. The proteins zinc finger 
protein SNAI1 (SNAIL), c-Jun N-terminal protein kinases (JNK), and MYC and 
Mitogen-Activated Protein Kinase Kinase Kinase 4 (MEKK4) are well-known 
suppressors of Pten transcription, among many others. In contrast, PPARγ and the p53 
pathway upregulate Pten transcription. The NOTCH1 pathway, which plays important 
roles in T cell development and Treg cell function (Asano et al., 2008; Charbonnier et al., 
2015; Deftos and Bevan, 2000), both positively and negatively regulates Pten 
transcription in a context-dependent manner (Salmena et al., 2008; Song et al., 2012).  
 
PTEN expression is also controlled at the post-transcriptional level.  First, 
endogenous, non-coding RNAs known as microRNAs (miRNAs) are essential regulators 
of PTEN expression. For instance, miR-19, miR-21, miR-26a and the miR-17~92 cluster, 
and miR-153 suppress PTEN expression (Huse et al., 2009; Meng et al., 2007; Olive et 
al., 2009; Song et al., 2012; Wu et al., 2013; Xiao et al., 2008). Additionally, post-
translational phosphorylation events regulate the function of PTEN. The phosphorylation 
of several C-terminal residues (S365, T366, T382, S385, and T388) of PTEN is 
associated with its localization and stability (Bermúdez Brito et al., 2015; Salmena et al., 
2008). In the context of diseases, the aberrant regulation of PTEN can occur at the 
genetic level. Allelic loss and mutations within different exons causes functional 
inactivation of PTEN. The loss of single PTEN allele is often seen in sporadic cancers, 
whereas homozygous loss is often correlated with advanced cancer and metastasis 
(Hollander et al., 2011; Pezzolesi et al., 2007; Song et al., 2012). We discuss the T cell-
specific control of PTEN later in this chapter.  
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Figure 1-6. PTEN gene structure. 
Structure of 403 amino acids long PTEN gene with five different functional domains.  
Reprinted with permission. Leslie, N.R., Batty, I.H., Maccario, H., Davidson, L., and 
Downes, C.P. (2008). Understanding PTEN regulation: PIP2, polarity and protein 
stability. Oncogene 27, 5464-5476. 
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Activation of mTOR by PTEN 
 
Many signals, including TCR, co-stimulatory, and cytokines, induce PI3K 
signaling in T cells (Chapman and Chi, 2014; Chi, 2012). PI3K phosphorylates the 
membrane lipid, PIP2, to generate PIP3. One function of PIP3 is to modulate protein 
localization by recruiting proteins with pleckstrin homology domains to the plasma 
membrane. PDK1 and AKT are two such proteins activated downstream of PI3K. 
Mechanistically, PDK1 phosphorylates AKT T308, and phosphorylation of AKT S473 by 
mTORC2 promotes maximum catalytic function of AKT. Active AKT drives cell 
survival, proliferation and cellular metabolism, in part by phosphorylation of the Foxo 
family proteins. AKT also activates mTORC1, which is a central regulator of cell 
metabolism, growth, proliferation and survival as discussed above (Figure 1-4) (Chi, 
2012). TCR/CD28-induced mTORC1 is activated via a PI3K-PDK1-dependent, AKT-
independent pathway in activated CTLs and Treg cells (Finlay et al., 2012; Wei et al., 
2016). Further, we found upregulation of the PI3K-PDK1 pathway is correlated with 
reduced Treg cell stability and function (Wei et al., 2016) Additionally, PI3K signaling is 
positively linked to mTORC2 activation, because PIP3 appears to directly activate 
mTORC2 kinase activity (Gan et al., 2011; Liu et al., 2015). Because PTEN controls the 
regulative balance of PIP3 available for driving PDK1, AKT, mTORC1, and mTORC2 
function, PTEN might also be an essential regulator of Treg survival, proliferation, 
stability or suppressive function. 
 
 
Regulation and roles of PTEN in T cells 
 
While PTEN expression is crucial for its function as a tumor suppressor, PI3K 
activation depends on downregulation of PTEN. Therefore, T cell responses, including 
proliferation and survival, depend on temporal instances of low PTEN expression. 
Studies have shown that TCR stimulation is sufficient to inhibit PTEN expression 
(Bensinger et al., 2004; Locke et al., 2009; Walsh et al., 2006), thus activating the PI3K 
pathway. However, CD28 costimulatory signals require PTEN (Buckler et al., 2006). It is 
also known that the expression of Pten is higher in Treg cells than in effector T cells 
(Bensinger et al., 2004; Zeiser et al., 2008). These results suggest that PTEN expression 
is a critical determinant of T cell functions. 
 
Conditional gene knockout and germline knockout approaches have been used to 
study the tumor suppressor function of PTEN. Initially, the role of PTEN in T cells was 
analyzed in Pten+/- mice, because complete disruption of Pten results in early embryonic 
lethality (Di Cristofano et al., 1998; Suzuki et al., 1998). These Pten+/- mice develop 
CD4+ T cell lymphoma and autoimmunity (Di Cristofano et al., 1999). To understand the 
intrinsic role of PTEN, Pten was conditionally deleted within the T cell compartment 
(Suzuki et al., 2001). Analyses of these mice demonstrated that the regulation of PIP3 
levels by PTEN is important for T-cell development and T-cell responses to activation 
and apoptotic-inducing signals. The analysis of T-cell conditional knockout mice 
revealed the loss of PTEN signaling during T cell lineage programming drives 
preferential TH2 differentiation (Buckler et al., 2008). Given the evidence that PTEN has 
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a profound impact on many aspects of T cell development and autoimmunity, one might 
predict that the Treg cell population would be altered in Pten conditional knockout mice. 
However, by using tissue-specific conditional deletion or transgenic mice, several groups 
have found that Treg cells appear to develop normally and their suppression ability seems 
to be intact in the absence of Pten ( Buckler et al., 2008; Walsh et al., 2006). 
Additionally, Pten-deficient Treg cells tend to be hyperpoliferative to IL-2 signaling 
alone due to the inability to activate PI3K (Walsh et al., 2006). In summary, studies have 
shown loss of PTEN function in T cells disrupts immune tolerance, but there is a need for 
further study to elucidate the role of PTEN specifically in Treg cells. 
 
 
Rationale and Hypothesis  
 
Although previous studies suggest PTEN is an important regulator of T cell 
selection and cell fate decisions, (Buckler et al., 2008; Walsh et al., 2006), those studies 
provided little direct evidence for a cell-intrinsic role for PTEN in Treg cell function. 
Therefore, we generated mice with a Treg-specific deletion of Pten to circumvent the 
potential influence of Pten deletion within multiple T cell populations. Using this system, 
we also minimize the undesired Cre-mediated toxicity (Schmidt-Supprian and Rajewsky, 
2007). The purpose of the study was to investigate the requirement of PTEN in the 
homeostasis and functions of Treg cells. We hypothesized that the loss of Pten in Treg 
cells would result in defective immune regulation. 
 
 
Conclusion 
 
Much of the recent emphasis has been placed on the roles of transcription factors 
that program Treg lineage stability and functional diversity, but how immunological 
signals are sensed and integrated by Treg cells to impinge upon distinct effector 
responses remains obscure. The data presented in this dissertation support a role for the 
PTEN-mTORC2 axis in regulating Treg cell stability and suppressive functions that 
dampen TH1 and TFH responses linked to systemic autoimmunity. Our results presented in 
Chapters 3 through 5 have led to a better understanding of how PTEN orchestrates Treg 
cell stability and functional diversity.  
 
Additionally, another project presented in Appendix (Figures A-1 to A-13) 
discusses how mTORC1 controls the function of memory T cells. The findings establish 
the role of the upstream mTORC1 regulator, TSC1 in immune signaling and cell 
metabolism necessary to orchestrate memory CD8+ T-cell differentiation and function. 
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CHAPTER 2.    METHODS AND MATERIALS* 
 
 
Mice 
 
Ptenfl/fl, CD45.1+, Rag1−/−, Ifng−/− and Rosa26GFP (harboring a loxP-site-flanked 
STOP cassette followed by the GFP-encoding sequence inserted into the Rosa26 locus) 
mice were purchased from the Jackson Laboratory. Rictorfl/flFoxp3-Cre mice have been 
described (Zeng et al., 2013). Foxp3YFP-Cre mice were a gift from Dr. A. Rudensky 
(Rubtsov et al., 2008) and Foxo1AAA/+, from Dr. M.O Li (Ouyang et al., 2012). 
Ptenfl/flFoxp3-Cre mice were analyzed at 10–12 weeks of age unless otherwise noted 
using age and sex-matched Foxp3-Cre mice as controls (referred to as WT). All mice 
were housed in a specific pathogen-free facility in the Animal Resource Center at St. 
Jude Children's Research Hospital. Animal protocols were approved by the Institutional 
Animal Care and Use Committee of St. Jude Children's Research Hospital.  
 
 
Bone Marrow Chimera 
 
Bone marrow (BM) chimeras were generated by transferring 7 × 106 T-cell–
depleted bone marrow cells into sublethally irradiated (5 Gy) Rag1−/− mice, followed by 
reconstitution for at least 2.5 months. Baytril water was used as an antibiotic treatment 
for BM chimeras for three weeks after irradiation. 
 
 
Polymerase Chain Reaction  
 
Polymerase chain reaction was used to genotype mice using primers (Invitrogen) 
listed in Table 2-1. A master mix of nuclease-free water, 1X Tsg enzyme buffer, 25 mM 
MgCL2, 10 mM dNTPs (all from Lamda Biotech), allele-specific primers and Tsg enzyme 
was prepared. Genomic DNA purified from mouse toe, tail, or ear clips was then added to 
each PCR reaction. Each set of PCR reactions also contained a positive and a negative 
control. Programs used to run the reaction in the thermal cycler are listed in Table 2-2. 
The samples were mixed with 6X DNA loading dye (Lamda Biotech) and loaded onto 
1% agarose gel. Bands were visualized with GelRed (Biotium) on a Gel Doc 2000 
(Biorad). The samples were scored according the band size listed in Table 2-1. 
 
 
Single Cell Suspension 
 
 Mice were sacrificed by CO2 asphyxiation and organs (spleen, mesenteric lymph 
and peripheral lymph nodes that included inguinal, auxiliary and cervical lymph nodes) 
------------------------ 
*Chapter 2 adapted with permission. Shrestha, S., Yang, K., Guy, C., Vogel, P., Neale, 
G., and Chi, H. (2015). Treg cells require the phosphatase PTEN to restrain TH1 and TFH 
cell responses. Nature immunology 16, 178-187.  
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Table 2-1. List of PCR primers used for PCR. 
 
Primer 
Name  Forward Primer  Reverse Primer  
Product 
Length (bp) 
Foxp3YFP
-Cre 
 
 AGGATGTGAGGGA
CTACCTCCTGTA 
 TCCTTCACTCTGAT
TCTGGCAATTT 
 346 
(knockin) 
 GCGTATGATCAGT
TATGCCTGTGTGG 
 CTGCCCTCCTAGA
TCATATCATCTGCC 
 423 (wild-
type) 
       
Pten  CAAGCACTCTGCG
AACTGAG 
 AAGTTTTTGAAGG
CAAGATGC 
 328 (loxP) 
156 (wild-
type) 
       
IFN-γ 
 
 
 
 AGAAGTAAGTGGA
AGGGCCCAGAAG 
 AGGGAAACTGGGA
GAGGAGAAATAT 
 320  
(mutant) 
 TCAGCGCAGGGGC
GCCCGGTTCTTT 
 ATCGACAAGACCG
GCTTCCATCCG 
 260 (wild-
type) 
       
Rictor 
 
 ACTGAATATGTTC
ATGGTTGTG 
 GAAGTTATTCAGA
TGGCCCAGC 
 554 (loxP) 
466 (wild-
type) 
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Table 2-2. PCR program used to amplify gene of interest. 
 
PTEN and IFN-γ  Foxp3YFP-Cre and Rictor 
94oC for 2:00 min  94oC for 2:00 min 
94oC for 0:45 min  94oC for 0:30 min 
65oC for 0:45 min  60oC for 0:30 min 
      - 0.3oC per cycle  72oC for 1:00 min 
72oC for 1:00 min  Goto 2, repeat 39 times 
Goto 2, repeat 41 times  72oC for 5:00 min 
72oC for 5:00 min  15oC for 5:00 min 
15oC for 5:00 min  End 
End   
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were harvested. The procedures here onwards were done in sterile conditions under the 
hood. Organs were placed in 10-cm petri dishes containing 1 mL of wash buffer (HBSS + 
2% FBS). 70-μm nylon mesh was laid over the organs, and the flat end of a 3 mL syringe 
was used to gently grind the organs to create single cell suspensions. The mesh was 
washed with wash buffer, and the cells were collected in a 15-mL conical tube. Cells 
isolated from the lymph nodes were used immediately for downstream assays. 
Splenocytes were centrifuged and then resuspended in 1 mL of ACK lysis buffer (Gibco). 
After 1-2 minutes, the cells were washed, centrifuged and resuspended in appropriate 
volume of wash buffer. 
 
 
Cell Purification 
 
Single cell suspensions from pooled spleen and peripheral lymph nodes were 
stained with magnetic L3T4 CD4+ T cell isolation microbeads (Miltenyi Biotech) for 15 
minutes at 4oC. The cells were subsequently washed and resuspended in wash buffer and 
filtered through a MACS MS column (Miltenyi Biotech) for positive selection of CD4+ T 
cells. The enriched cells were washed and stained with the appropriate surface markers 
for 30 minutes in 4oC. Cells were then washed, and naïve and Treg cells were sorted 
using a MoFlow (Beckman-Coulter) or Reflection (i-Cyt) fluorescence-based cell sorter 
based on the surface markers listed in Table 2-3.  
 
 
Flow Cytometry 
 
For analysis of surface markers, cells were stained in FACS buffer (PBS 
containing 2% (wt/vol) bovine serum albumin (BSA)). The following antibodies were 
used for flow cytometry analysis: anti-CD4 (RM4-5), anti-CD8α (53-6.7), anti-TCRβ 
(H57-597), anti-CD69 (H1.2F3), anti-CD25 (PC61.5), anti-CD44 (1M7), anti-CD62L 
(MEL-14), anti-CD45.1 (A20), anti-CD45.2 (104), anti-PD-1 (J43), anti-GL7 (GL-7), 
anti-CD95 (15A7), anti-ICOS (C398.4A), anti-GITR (DTA-1), anti-CD19 (1D3), anti-
CXCR3 (CXCR3-173), anti-MHCII (M5/114.15.2), anti-CD11b (M1/70), anti-CD11c 
(N418), anti-Ly6G (RB6-8C5; all from eBioscience). CXCR5 was stained with 
biotinylated anti-CXCR5 (clone 2G8) followed by streptavidin-conjugated PE (both from 
BD Biosciences). Flow cytometry data were acquired on the LSRII or LSR Fortessa flow 
cytometer (BD Biosciences) and analyzed using Flowjo software (Tree Star). 
 
 
Intracellular Staining  
 
For intracellular marker staining, single cell suspensions were resuspended in 
FACS buffer containing antibodies for surface markers and incubated for 30 minutes in 
4oC. The stained cells were then washed with ice-cold FACS buffer and fixed using 
fixation/permeabilization buffer (ebioscience, catalog # 005123-43). One hour later, cells 
were washed with 1X permeabilization buffer (ebioscience, catalog # 008333-56) twice 
and then stained with intracellular markers for 20 minutes at 4oC. Anti-Foxp3 (FJK-16s), 
 27 
Table 2-3. Characterization of innate and adaptive immune cell surface and 
intracellular markers. 
 
Cell Population  Cell Markers 
Naïve T cells  CD62L+ CD44- 
Activated T cells  CD44+ CD62L- 
Treg cells  CD4+ TCRβ+ YFP+ or 
CD4+ TCRβ+ Foxp3+ 
TFH  CD4+ CXCR5+ PD-1+ or 
CD4+ CXCR5+ ICOS+ or 
CD4+ CXCR5+ Bcl6+ 
GC B cells  CD4- CD19+ GL7+ CD95+ 
TFH  CD4+ CXCR5+ PD-1+ 
YFP+  
TH1  CD4+ TCRβ+ IFN-γ  
TH17  CD4+ TCRβ+ IL-17+ 
TH2  CD4+ TCRβ+ IL-4+ 
B cells  CD4- CD19+ 
DC  MHCII+ CD11c+ 
Neutrophils  Ly6G+ CD11b+ 
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anti-T-bet (4B10), anti-IRF4 (3E4), anti-IFN-γ (XMG1.2), anti-IL-4 (11B11), and anti-
IL-17 (17B7) antibodies were all from eBioscience. Anti-CTLA4/CD152 (UC10-4B9) 
and anti-Blimp1 (3H2-E8) were purchased from Biolegend and Thermo Scientific, 
respectively. Cells were then washed and analyzed by flow cytometry. 
 
For intracellular cytokine staining, T cells were stimulated for 4 h with 50ng/ml 
PMA plus 1 μg/ml ionomycin in the presence of 1X monensin (GolgiSTOP, BD 
Bioscience) in 48-well plates at 37oC + 5% CO2. Cells were harvested, stained, and 
processed for flow cytometric analysis as above. 
 
For phospho antibody staining, cells were incubated in pre-warmed 1X Phosflow 
lyse/fix buffer (BD Biosciences) at 37oC for 10 minutes. Cells were then pelleted by 
centrifugation and washed once with FACS buffer. After washing, the cells were 
permeabilized by adding 1 mL of ice-cold Phosflow Perm Buffer III (BD Biosciences), 
and incubated in ice for 30 minutes. The cells were washed twice with FACS buffer, 
stained with antibodies specific for as p-STAT3 (4/P-STAT3), PTEN (A2B1), and Bcl6 
(K112-91; all from BD Biosciences) for 1 h at room temperature, and processed for flow 
cytometric analysis. 
 
 
Cell Proliferation Assay 
 
Mice were injected intraperitoneally (i.p) with 1mg of 5-Bromo-2’-deoxyuridine 
(BrdU) stock 16 hours before analysis. Single cell suspensions were prepared from 
spleen, peripheral and mesenteric lymph nodes and thymus. Cells were stained with 
antibodies specific for cell-surface markers for 30 minutes at 4oC, washed and 
resuspended in Cytofix/Cytoperm buffer for 15 minutes on ice. Cells were then washed 
with Perm/Wash buffer, incubated in Cytoperm Plus buffer for 10 min on ice, washed 
again with Perm/Wash buffer and resuspended in Cytofix/Cytoperm buffer. After 5 min 
incubation on ice, cells were washed with Perm/Wash buffer, resuspended in PBS 
containing 300 ug/ml of DNase I and incubated for 1 h at 37˚C. After washing with 
Perm/Wash buffer, cells were stained with anti-BrdU (BD Pharmingen) and processed for 
flow cytometric analysis. All buffers and additional reagents described in this protocol 
were obtained from BD Biosciences (552598). 
 
 
Active Caspase-3 Staining  
 
Cells obtained from single cell suspension were first stained with cell surface 
makers for 30 minutes at 4oC deg, washed and then fixed using BD Cytofix/Cytoperm 
buffer on ice for 20 minutes. Cells were washed twice using BD Perm/Wash buffer and 
stained with active Caspase-3 at room temperature for 30 minutes and then processed for 
flow cytomeric analysis. All buffers and additional reagents described in this protocol 
were in the active caspase-3 apoptosis kit (550941) purchased from BD Pharmingen. 
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Active Mitochondria Staining 
 
For staining mitochondria, lymphocytes were incubated for 30 min at 37 °C with 
10 nM MitoTracker Deep Red (Life Technologies) or 20 nM TMRM (tetramethyl 
rhodamine, methyl ester; ImmunoChemistry Technologies) after staining surface 
markers. ROS were measured by incubation with 5 μM MitoSOX Red (Life 
Technologies) after staining surface markers. The samples were then analyzed by flow 
cytometry.  
 
 
Immunofluorescence 
 
For cryosections, kidneys and MLNs were freshly frozen in OCT embedding 
medium (Ploysciences, Inc). 10-μm-thick cryosections were fixed with cold acetone for 5 
min before rehydration in Tris-buffered saline (TBS). Nonspecific binding was blocked 
by incubation in TBS containing 2% BSA and 5% normal donkey serum for 30 min 
before incubation with primary antibodies (2 μg/ml) overnight at 4 °C. Slides were 
washed for 15 min in TBS before incubation with Alexfluor568-conjugated goat anti-
mouse antibody (1 μg/ml; A11031; Life Technologies), Alexfluor568-conjugated donkey 
anti-goat antibody (1 μg/ml; A11057; Life Technologies), Cy5-conjugated donkey anti-
goat antibody (1 μg/ml; 705-175-147; Jackson ImmunoResearch), or Alexfluor488-
conjugated streptavidin (1 μg/ml; S11223; Life Technologies) for 1 h at room 
temperature. Slides were washed for 15 min in TBS before mounting in Vectashield hard 
set with DAPI (Vector Laboratories). Fluorescence images were acquired using a Zeiss 
Axiovert200M and 20X EC Plan-NeoFluar objective, detected using a Cascade II 
EMCCD camera (Photometrics) and analyzed using Slidebook software (3i Intelligent 
Imaging Innovations). Large image composites were acquired with a Nikon Ti-E inverted 
microscope with 20× CFI Plan Apochromat Lambda objective and iXon DU897 EMCCD 
camera, using NIS-Elements software.  
 
Visualization of ANA antibodies was performed by staining fixed Hep-2 slides 
(MBL). Specifically, serum samples were applied to the slide and incubated for 2 h at 
room temperature followed by 15 min washing in TBS. Bound murine antibodies were 
detected using Alexfluor568-conjugated goat anti-mouse antibody (1 μg/ml; A11031; 
Life Technologies) for 1 h at room temperature, and Alexafluor488-conjugated phalloidin 
(A12379; Life Technologies) was used to visualize F-actin, and nuclei were detected 
using DAPI. The anti-CD3 (sc-1127 (M-20)) antibody was purchased from Santa Cruz, 
Biotinylated Peanut Agglutinin (PNA) from Vector Laboratories (B-1075), and IgD 
(558597) from BD Biosciences. 
 
 
Immunohistochemistry 
 
For paraffin sections, the spleen, kidney and Peyer's patches were fixed by 
immersion in 10% (vol/vol) neutral buffered formalin solution. Fixed tissues were 
embedded in paraffin, sectioned and stained with hematoxylin and eosin, and the clinical 
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signs of autoimmune diseases were analyzed by an experienced pathologist (Dr. Peter 
Vogel), blinded to sample identity. 
 
 
Immunization 
 
For experiments involving antigen-induced TFH and GC B cell response, antigen 
for immunization was prepared by mixing NP14-OVA (14 molecules of NP linked to 
OVA; Biosearch Technologies) and 10% KAl(SO4)2 dissolved in PBS at a ratio of 1:1, in 
the presence of LPS (Escherichia coli strain 055:B5; Sigma). The solution was set to pH 
7, and NP-OVA (100 μg) and LPS (10 μg) precipitated in alum was injected 
intraperitoneally as described (Kang et al., 2013).  
 
Alternatively, a fresh preparation of 1 × 109 PBS-washed 1 × 109 SRBCs from 
Colorado Serum Company (31112) were injected intravenously to induce a robust splenic 
GC response (Cato et al., 2011). 
 
 
Serum Antibodies 
 
100μl of blood from WT and Ptenfl/flFoxp3-Cre mice was collected in 1.5ml tubes 
and placed at room temperature for 30 minutes. The tube containing the blood was then 
centrifuged in 1000g for 10 minutes. The supernatant was then used for autoantibodies 
(dsDNA) and immunoglobulin subclasses detection assays with kits from Alpha 
Diagnostic International (5110) and Millipore (MGAMMAG-300K), respectively. 
 
 
Adoptive Transfer 
 
For adoptive transfer, sorted CD4+CD25+Foxp3-YFP+cells from Foxp3-Cre 
and Ptenfl/flFoxp3-Cre mice (CD45.2+) were transferred to the congenically marked 
(CD45.1+) recipients. Seven days after the transfer, mice were euthanized for the analysis 
of Foxp3 and CD25 expression. 
 
 
Cell Counting 
  
The automated Nexcelom Bioscience Cellometer Auto T4 was used to count cell 
numbers. Alternatively, the cell suspension was mixed with trypan blue and counted 
using hemocytometer chamber. 
 
Cells per ml = the average count per square x the dilution factor x 104 
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Quantitative RT-PCR 
 
RNA was extracted from cells using the RNeasy micro kit (Qiagen), and cDNA 
was synthesized with SuperScript III reverse transcriptase (Invitrogen). An ABI 7900 
Real-time PCR system was used for quantitative PCR, with primer and probe sets from 
Applied Biosystems. The probes were (Pten, Mm00477208_m1), Ifng (forward - 
TCGAATCGCACCTGATCACTA; reverse – GGGTTGTTCACCTCGAACTTG and 
probe – CATCCTTTTTTGCTTTACTGTTGCTGAAGAAG).  
 
Results were analyzed with SDS 2.1 software and in Graphpad prism. The cycling 
threshold value of the endogenous control gene (β-actin) was subtracted from the cycling 
threshold value of each target gene to generate the change in cycling threshold (DeltaCT). 
The expression of each target gene is presented as the fold change relative to that of wild-
type unstimulated samples using the delta delta CT method (Menon et al., 2007). 
 
 
Immunoblotting 
 
For immunoblotting, the immunoprecipitates or whole-cell lysates were resolved 
on SDS-PAGE gels and transferred to polyvinylidene difluoride membranes (Bio-Rad) 
and blocked using 5% non-fat milk (Bio-rad) in TBST (1X TBS from Bio-rad containing 
0.1% Tween-20). The membranes were incubated with various antibodies diluted in 5% 
Bio-Rad blocking buffer and washed using 0.1% TBST. The bound antibodies were 
visualized with Horseradish peroxidase (HRP) conjugated antibodies against mouse or 
rabbit IgG by using SuperSignal West Dura Extended Duration Substrate (Thermo Fisher 
Scientific). The images were obtained using film.  
 
Primary antibodies used were the following: anti-p-S6 (Ser235/236) (2F9, Cell 
Signaling Technology), anti-p-4E-BP1 (Thr37/46) (236B4, Cell Signaling Technology), 
anti-p-Foxo1 (Ser256) (9461, Cell Signaling Technology), anti-p-AKT S473 (D9E, Cell 
Signaling), anti-PTEN (138D6; Cell Signaling Technology) and anti-β-actin (AC-15; 
Sigma). The primary antibody dilutions were 1:1,000 (phospho-antibodies and PTEN 
antibody) and 1: 2,000 (β-actin antibody). 
 
 
Glycolysis Assay 
 
Treg cells were stimulated with plate-bound anti-CD3-CD28 for 6 h, and 
glycolytic flux was measured by detritiation of [3-3H]-glucose, as described (Shi et al., 
2011).  
 
 
Gene-expression Profiling and Gene-set Enrichment Analysis 
 
DNase-treated RNA samples from sort-purified WT or PTEN-deficient Treg cells 
were analyzed with the Affymetrix HT MG-430 p.m. GeneTitan peg array, and 
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expression signals were summarized with the robust multi-array average algorithm 
(Affymetrix Expression Console v1.1). Lists of genes differentially expressed by 1.5-fold 
or more were analyzed for functional enrichment using the Ingenuity Pathways 
(http://www.ingenuity.com). GSEA within canonical pathways was performed as 
described (Subramanian et al., 2005). The microarray data have been deposited into the 
GEO series database (GSE63625). 
 
 
Statistical Analysis 
 
P values were calculated with Student's t-test (GraphPad Prism). P < 0.05 was 
considered significant. All error bars represent mean and s.e.m. 
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CHAPTER 3.    CHARACTERIZATION OF IMMUNOLOGICAL EFFECTS 
MEDIATED BY PTEN SIGNALING IN TREG CELLS* 
 
 
Introduction 
 
We and others have shown a central role for mTOR in T cell-mediated immune 
responses (Chi, 2012; Powell et al., 2012). As mTOR is activated by diverse upstream 
signals and serves multifactorial roles in T cell responses, multiple mechanisms actively 
enhance or suppress mTOR signaling (Chi, 2012). For instance, loss of the tumor 
suppressor TSC1 aberrantly upregulates mTORC1 activity and disrupts T cell 
quiescence, homeostasis and functions (Yang et al., 2011). As a pluripotent molecule, 
PTEN antagonizes PI3K activity and thus has been shown to inhibit both mTORC1 and 
mTORC2 complexes (Chi, 2012); Deletion of Pten in T cells leads to the development of 
leukemia and autoimmunity (Liu et al., 2010; Suzuki et al., 2001). PTEN also possesses 
nuclear functions independent of PI3K-AKT activity (Song et al., 2011). Although PTEN 
has been implicated in the homeostasis and abundance of Treg cells (Bensinger et al., 
2004; Zanin-Zhorov et al., 2012), previous studies have demonstrated Pten-deficient Treg 
cells maintain their suppressive activity in vitro (Walsh et al., 2006). Therefore, the 
functional impacts and molecular pathways of PTEN in Treg cell-mediated immune 
homeostasis and function remain to be established. 
 
 To investigate the in vivo functions and mechanisms of PTEN in Treg cells, we 
developed a mouse model to delete Pten selectively in Treg cells. Treg-specific loss of 
Pten was sufficient to induce a systemic, lupus-like autoimmune and lymphoproliferative 
disease. This disorder was associated with excessive TFH and GC B cell responses, as 
well as exuberant IFN-? production and TH1 reactions. Importantly, deletion of IFN-? 
considerably rectified TFH and autoimmune responses, indicating that PTEN signaling in 
Treg cells coordinately regulates TH1 and TFH responses. 
 
 
Treg Cell-specific Deletion of PTEN Precipitates an Inflammatory Disease 
 
 
Generation of Pten-deficient Treg cell mice 
 
To better understand the role of PTEN in the homeostasis and functions of 
Treg cells in vivo, we crossed mice carrying loxP-flanked Pten alleles (Ptenfl/fl) 
with Foxp3YFP-Cre (Foxp3-Cre) mice (Rubtsov et al., 2008) to generate mice in which 
the Pten conditional alleles are deleted specifically in Treg cells (referred to as  
 
 
------------------------ 
*Chapter 3 reprinted with permission. Shrestha, S., Yang, K., Guy, C., Vogel, P., Neale, 
G., and Chi, H. (2015). Treg cells require the phosphatase PTEN to restrain TH1 and TFH 
cell responses. Nature immunology 16, 178-187. 
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Ptenfl/flFoxp3-Cre mice). PTEN was deleted efficiently at both at the mRNA and protein 
levels in Treg cells but not in other T cell subsets (Figure 3-1).  
 
 
Phenotypic characterization of Ptenfl/flFoxp3-Cre mice  
 
Ptenfl/flFoxp3-Cre mice were phenotypically indistinguishable from littermate 
controls (Foxp3-Cre mice, designated as WT) from birth to 2-3 months of age. However 
4-5-months-old Ptenfl/flFoxp3-Cre mice spontaneously developed cervical lymph node 
hyperplasia at. At this age, the Ptenfl/flFoxp3-Cre mice also displayed modest 
splenomegaly (Figure 3-2A).  
 
Next, we wanted to assess if there was a global inflammatory response in 
Ptenfl/flFoxp3-Cre mice. Routine histological examination by H&E staining was 
conducted in groups of mice at different age intervals. Most of the organs in 
Ptenfl/flFoxp3-Cre mice had multifocal inflammation (unpublished observations). 
Interestingly, the number and size of reactive follicles in Peyer’s patches were greater in 
Ptenfl/flFoxp3-Cre mice than WT mice (Figure 3-2B). This finding of Peyer’s patch 
abnormality and the spontaneous development of lymphoadenopathy in Ptenfl/flFoxp3-
Cre mice indicated an ongoing lymphoproliferative disease, although it was not lethal and 
no signs of malignancies were identified. The affected mice were able to survive more 
than a year (unpublished observations). 
 
 
Disruption of immune system in Ptenfl/flFoxp3-Cre mice 
 
To clarify if the pathology of Ptenfl/flFoxp3-Cre mice was related to the 
development of a systemic autoimmune disease rather than lymphoma, we quantified 
total antibody and autoantibody activity in the serum of WT or Ptenfl/flFoxp3-Cre mice. 
The amounts of anti-dsDNA and anti-nuclear antigen (ANA) autoantibodies in the serum 
were measured using ELISA and binding to fixed Hep-2 slides, respectively. We found 
significantly increased titers of circulating anti-dsDNA and ANA antibodies in 
Ptenfl/flFoxp3-Cre mice compared with WT (Figure 3-3A and B), indicative of 
autoimmune reactions. Furthermore, upon examination of mouse immunoglobulin 
isotypes, we found considerably elevated titers of serum IgG2a/c and IgG2b isotypes in 
Ptenfl/flFoxp3-Cre mice. In contrast, IgG1 and IgG3 titers were reduced, while IgM and 
IgA titers were comparable between WT and Ptenfl/flFoxp3-Cre mice (Figure 3-4).  
 
Lymphocytic infiltration leading to predominant renal nephritis is frequently 
associated with clinical manifestations of systemic or non-organ specific autoimmune 
diseases. We therefore examined the glomerular architecture of the kidney in 
Ptenfl/flFoxp3-Cre mice. To our expectation, the size and cellularity of the glomeruli were 
greatly increased in the kidney from Ptenfl/flFoxp3-Cre mice, indicative of 
glomerulonephritis (Figure 3-5). Furthermore, immunofluorescence imaging revealed 
prominent IgG deposits in the kidney glomeruli of Ptenfl/flFoxp3-Cre mice (Figure 3-6). 
In summary, these results highlight that loss of Pten in Treg cells results in the 
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Figure 3-1. Analysis of Pten mRNA and PTEN protein expression in Treg cells. 
Real-time PCR analysis of Pten mRNA expression in Treg and naïve CD4+ T cells (left) 
and histogram from flow cytometry analysis showing PTEN protein expression in 
CD4+YFP+, CD4+YFP– and CD8+ T cells from the spleen of WT and Ptenfl/flFoxp3-Cre 
mice (right). Results were normalized using β-actin housekeeping gene and expressed as 
fold change for real-time PCR. 
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Figure 3-2. Age-related lymphoproliferative disease seen in Ptenfl/flFoxp3-Cre 
mice. 
(A) Images of spleen and peripheral lymph nodes from WT (upper, ~5 months old), 
Ptenfl/flFoxp3-Cre mice prior to the development of lymphoproliferative disease (middle, 
~2.5 months old), and Ptenfl/flFoxp3-Cre with lymphoproliferative disease (lower, ~5 
months old). (B) Hematoxylin and eosin (H&E) staining of Peyer’s patches in the 
intestine of WT and Ptenfl/flFoxp3-Cre mice (magnification: left, x4; and right, x20). 
  
 37 
 
Figure 3-3. Ptenfl/flFoxp3-Cre mice develop spontaneous systemic autoimmune disease.  
(A) Quantification of dsDNA-specific IgG in the serum of WT and Ptenfl/flFoxp3-Cre (2-6 months old; WT, n = 19; Ptenfl/flFoxp3-Cre, 
n = 24). (B) Immunofluorescence image (scale 20 μm) and quantification of fluorescent intensity (right) of serum ANA IgG 
autoantibodies detected with fixed Hep-2 slides. Data are mean ± s.e.m. *P < 0.05 and **P < 0.001. 
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Figure 3-4. Dysregulation of immunoglobulins isotype in Ptenfl/flFoxp3-Cre mice. 
Quantification of IgG subclasses, IgM and IgA in the serum of WT and Ptenfl/flFoxp3-Cre mice (the IgG2a binding antibody shows 
cross-reactivity with IgG2c). Data are mean ± s.e.m. NS, not significant; *P < 0.05, **P < 0.01 and ***P < 0.001. 
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Figure 3-5. Structural integrity of the kidney in WT and Ptenfl/flFoxp3-Cre mice. 
Representative images of kidney glomerulus sections stained with H&E stain (magnification: x60, scale bar 50 μm). The size and 
cellularity of the glomeruli of Ptenfl/flFoxp3-Cre mice (right) were greatly increased in the kidney, indicative of glomerulonephritis. 
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Figure 3-6. Imaging analysis of kidney glomeruli of Ptenfl/flFoxp3-Cre mice. 
Immunofluorescence images (left) and quantification (right) of kidney glomerulus sections showing IgG deposits (scale 20 μm) in WT 
and Ptenfl/flFoxp3-Cre mice. Data are mean ± s.e.m. **P < 0.001. 
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development of a systemic autoimmune disorder characterized by aberrant antibody 
responses. 
 
 
Altered Immune Homeostasis upon Treg-specific Loss of PTEN 
 
Disturbances in homeostasis cause T cells to upregulate effector functions, and 
this processes can contribute to autoimmune manifestations (Theofilopoulos et al., 2001). 
The development of the autoimmune and lymphoproliferative disease prompted us to 
examine whether homeostasis of the immune system was altered in Ptenfl/flFoxp3-Cre 
mice. In our following analyses, we used mice at a young age, prior to the development 
of the lymphoproliferative disease. 
 
 
PTEN is essential for Treg cell-mediated immune homeostasis 
 
In the steady-state environment, WT and Ptenfl/flFoxp3-Cre mice had comparable 
numbers of CD4+or CD8+ T cells, B cells, dendritic cells, and neutrophils (Figure 3-7). 
However, the numbers of activated CD62LloCD44hi effector/memory T cells in the CD4+ 
and CD8+ compartments were increased in Ptenfl/flFoxp3-Cre mice (Figure 3-8). 
Moreover, CD44hi cells from these mice expressed elevated levels of IFN-?  
(Figure 3-9A). Similarly, expression of CXCR3, the signature chemokine receptor of 
TH1 cells, was also elevated (Figure 3-9D). In contrast, IL-17 and IL-4 production was 
largely normal (Figure 3-9B and C). Thus, T cells from Ptenfl/flFoxp3-Cre mice were 
spontaneously activated in vivo, with a propensity to differentiate into the TH1 phenotype. 
Despite severe autoimmune diseases, Ptenfl/flFoxp3-Cre mice had increased percentage 
and numbers of Foxp3+ Treg cells in the spleen and lymph nodes (Figure 3-10A).  
 
 
Cell death and proliferation in Pten-deficient Treg cells 
 
To explore the underlying basis for the increased Treg cellularity, we used 
caspase-3 staining and BrdU incorporation assays to measure Treg cells apoptosis and 
proliferation, respectively. Treg cells from WT and Ptenfl/flFoxp3-Cre mice had 
comparable caspase-3 staining (Figure 3-10B), but Ptenfl/flFoxp3-Cre Treg cells had 
more BrdU incorporation than WT cells (Figure 3-10C), indicative of an elevated rate of 
proliferation. Therefore, Pten deficiency causes an increased Treg cellularity and 
proliferation.  
 
Uncontrolled TFH Responses and GC B Cells in Pten-deficient Treg Mice 
 
Systemic lupus erythematosus (SLE), the prototypical systemic autoimmune 
disease, is characterized by the heterogeneity of the underlying T cell responses. Aside 
from the roles of the conventional effector (e.g. TH1 and TH17) and regulatory responses, 
recent studies demonstrate a crucial role of TFH cells in the overproduction of pathogenic 
autoantibodies and tissue damage in SLE (Crotty, 2011; Linterman et al., 2009). 
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Figure 3-7. Flow cytometric analysis of different immune cell populations. 
(A) Analysis and quantification of CD4+ and CD8+ T cells (B) B cells, (C) conventional 
dendritic cells (MCHII+CD11c+) and neutrophils (Ly6G+CD11b+) in the spleen of WT 
and Ptenfl/flFoxp3-Cre mice. Numbers indicate percentage of cells in quadrants or gates. 
Data are mean ± s.e.m. NS, not significant. 
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Figure 3-8. Altered T cell homeostasis in Ptenfl/flFoxp3-Cre mice. 
Expression of CD62L and CD44 on WT and Ptenfl/flFoxp3-Cre splenic T cells. Numbers 
indicate percentage of cells in quadrants or gates. Ptenfl/flFoxp3-Cre mice have a higher 
frequency of activated CD44hiCD62Llo and a lower frequency of naïve CD44loCD62Lhi T 
cells. Numbers indicate percentage of cells in quadrants or gates. 
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Figure 3-9. TH1 immune responses are increased in Ptenfl/flFoxp3-Cre mice. 
Expression of (A) IFN-γ, (B) IL-4 and (C) IL-17 in CD4+ and CD8+ T cells of WT and Ptenfl/flFoxp3-Cre mice after in vitro 
stimulation for 4 h with phorbol 12-myristate 13-acetate (PMA) plus ionomycin in the presence of monensin. Numbers indicate 
percentage of cells in quadrants or gates. (D) Expression of CXCR3 on CD4+ T cells from the spleen of WT and Ptenfl/flFoxp3-Cre 
mice. Numbers in the graph indicate mean fluorescence intensity of CXCR3.  
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Figure 3-10. Ptenfl/flFoxp3-Cre mice have an increased frequency of Treg cells. 
(A) Flow cytometric analysis of Treg cells in WT and Ptenfl/flFoxp3-Cre splenic CD4+ T 
cells. (B) Caspase-3 activity and (C) BrdU incorporation in Treg cells from the spleen or 
peripheral lymph nodes (PLN) at 16 h after BrdU injection in WT and Ptenfl/flFoxp3-Cre 
mice. Numbers indicate percentage of cells in quadrants or gates. 
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The development of SLE-like symptoms in Ptenfl/flFoxp3-Cre mice prompted us 
to examine whether the TFH response was altered in these mice. Under steady state, only a 
small percentage of WT splenic CD4+ T cells were stained positive for the TFH signature 
molecules, CXCR5 and PD-1, but the CD4+CXCR5+PD-1+ population was greatly 
expanded in the spleen and MLNs of Ptenfl/flFoxp3-Cre mice (Figures 3-11A and  
3-12A). Similar changes were noticed for CXCR5+ cells expressing the TFH-associated 
co-stimulatory molecule ICOS and the transcription factor Bcl6 (Figure 3-12B and C). 
The CD4+CXCR5+PD-1+ cells can be further divided into immunostimulatory TFH and 
immunoregulatory TFR cells, as indicated by the absence or presence of Foxp3 
expression, respectively (Chung et al., 2011; Linterman et al., 2011). Both subsets were 
increased in Ptenfl/flFoxp3-Cre mice (Figure 3-11B). Consistent with the increase of 
CXCR5+PD-1+ cells, the spleen and MLNs of Ptenfl/flFoxp3-Cre mice contained 3-fold 
more GC B cells, denoted by the expression of GC signature markers GL7 and CD95 
(Figures 3-11C and 3-12D), even though total B cell numbers were largely unaltered 
(Figure 3-7B). Moreover, immunohistochemistry showed that the spleen and MLNs of 
Ptenfl/flFoxp3-Cre mice contained considerably more and larger peanut agglutinin (PNA)-
positive GCs than did their WT counterparts (Figure 3-13A and B). These results 
revealed spontaneous TFH and GC formation in Ptenfl/flFoxp3-Cre mice.  
 
We next determined whether Pten deficiency in Treg cells affects TFH and GC 
responses after TFH-inducing immunization. After immunization with sheep red blood 
cells (SRBCs), a strong protein antigen, the formation of TFH cells and GC B cells was 
greatly enhanced in Ptenfl/flFoxp3-Cre mice compared with WT mice (Figure 3-14A). 
We observed a similar finding after challenging WT and Ptenfl/flFoxp3-Cre mice with a T 
cell-dependent antigen, NP-OVA precipitated in alum and LPS (Figure 3-14B). We 
conclude that deletion of Pten in Treg cells results in enhanced TFH and GC reactions 
both under steady state and upon immunization.  
 
 
Coordination of TH1 and TFH Responses by PTEN Signaling in Treg Cells 
 
We next investigated whether the increased TFH response in Ptenfl/flFoxp3-Cre 
mice was a cell-autonomous defect. To this end, we generated mixed bone marrow (BM) 
chimeras by reconstituting alymphoid Rag1–/– mice with a 1:1 mixture of Ptenfl/flFoxp3-
Cre CD45.2+ (donor) and CD45.1+ (spike) BM cells (denoted as Ptenfl/flFoxp3-
Cre:CD45.1+), and as a control, a mixture of WT and CD45.1 cells (denoted as 
WT:CD45.1+). The frequency of TFH cells was considerably increased in both the donor 
and spike-derived populations in the Ptenfl/flFoxp3-Cre:CD45.1+ chimeras, as compared 
with the frequency of TFH cells in the WT:CD45.1+ chimeras (Figure 3-15A). 
Additionally, Ptenfl/flFoxp3-Cre:CD45.1+ chimeras had augmented GC B cells  
(Figure 3-15B). Thus, Pten deficiency in Treg cells results in a dominantly acting effect 
on the TFH and GC responses.  
 
The TH1 cytokines such as IFN-? have been implicated in potentiating TFH 
responses (Lee et al., 2012a), although opposing evidence also exists (Nakayamada et al., 
2011; Ray et al., 2014), suggesting a context-dependent effect. We therefore explored 
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Figure 3-11. Aberrant TFH, TFR and GC B cells responses in Ptenfl/flFoxp3-Cre 
mice. 
(A) Left, flow cytometry analysis of TFH cells (CXCR5+PD-1+) cells (gated on 
CD4+TCRβ+ cells) in the spleen of WT and Ptenfl/flFoxp3-Cre mice. Right, the frequency 
and numbers of TFH cells. (B) Left, analysis of conventional TFH (CD4+CXCR5+PD-
1+Foxp3-YFP–) and TFR cells (CD4+CXCR5+PD-1+Foxp3-YFP+) in the spleen of WT and 
Ptenfl/flFoxp3-Cre mice. (C) Left, analysis of GL7+CD95+ GC B cells (gated on CD19+ B 
cells) in the spleen of WT and Ptenfl/flFoxp3-Cre mice. Right, the frequency and numbers 
of GC B cells. Numbers indicate percentage of cells in quadrants or gates. Data are mean 
± s.e.m. *P < 0.05 and **P < 0.01. 
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Figure 3-12. Analysis of TFH and GC B cells. 
(A) Flow cytometry of CXCR5 and PD-1 expression (gated on CD4+TCRβ+ cells) in the 
MLNs of WT and Ptenfl/flFoxp3-Cre mice. Flow cytometry of (B) CXCR5 and ICOS and, 
(C) CXCR5 and Bcl6 expression (gated on CD4+TCRβ+ cells) in the spleen and MLNs of 
WT and Ptenfl/flFoxp3-Cre mice. (D) Flow cytometry of GL7 and CD95 expression 
(gated on CD19+ cells) in the MLNs of WT and Ptenfl/flFoxp3-Cre mice.  
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Figure 3-13. Immunochistochemistry of germinal centers in WT and Ptenfl/flFoxp3-
Cre mice. 
(A) Germinal center (brown) defined by peanut agglutinin (PNA) staining of spleen 
sections of WT and Ptenfl/flFoxp3-Cre mice (magnification, x4; scale bars, 1mm). (B) 
Immunofluorescence of germinal center in MLN sections of WT and Ptenfl/flFoxp3-Cre 
mice defined by the staining of CD3 (red, marking T cell zones) and PNA (green) (scale 
60 μm). 
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Figure 3-14. Induction of germinal center responses in WT and Ptenfl/flFoxp3-Cre 
mice. 
Analysis and quantification of TFH and GC B cells in the spleen of WT and Ptenfl/flFoxp3-
Cre mice immunized with (A) SRBCs and (B) NP-OVA 7 days previously. Numbers 
indicate percentage of cells in quadrants or gates. Data are mean ± s.e.m. *P < 0.05 and 
**P < 0.01. 
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Figure 3-15. Analysis of bone marrow-derived chimeras reveals dysregulated TFH 
and GC B cell responses and IFN-γ overproduction in Ptenfl/flFoxp3-Cre mice. 
Sublethally irradiated Rag1–/– mice were reconstituted with a 1:1 mix of CD45.1+ bone 
marrow (BM) cells with either CD45.2+ WT or Ptenfl/flFoxp3-Cre BM cells. Following 
reconstitution, the mixed chimeras were analyzed for (A) TFH, (B) GC B cells and 
intracellular staining of IFN-γ in (C) CD4+ and (D) CD8+ T cells. Numbers indicate 
percentage of cells in quadrants or gates. 
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whether dysregulated cytokine production was observed in Ptenfl/flFoxp3-Cre:CD45.1+. 
In the Ptenfl/flFoxp3-Cre:CD45.1+ mixed chimeras, IFN-? production from CD4+ and 
CD8+ T cells was enhanced irrespective of the source of donor cells (Figure 3-15C  
and D).  
 
To determine the functional effects of the augmented IFN-? production, we 
crossed Ptenfl/flFoxp3-Cre mice with Ifng–/– mice to generate Ptenfl/flFoxp3-Cre Ifng–/– 
double knockout mice (Figure 3-16A). Deletion of IFN-? did not exert strong effects on 
the production of IL-17 and IL-4 from the conventional CD4+ T cells  
(Figure 3-16B and C). However, IFN-? deficiency substantially blocked the elevated 
frequencies of TFH and GC B cells (Figure 3-17A and B) and the increased formation of 
GCs in Ptenfl/flFoxp3-Cre mice (Figure 3-18). Moreover, the increased production of 
serum ANA antibody and the deposition of IgG in the kidney glomeruli of Ptenfl/flFoxp3-
Cre mice were essentially rectified in Ptenfl/flFoxp3-Cre Ifng–/– mice  
(Figures 3-19 and 3-20). Thus, the increased production of IFN-? in Ptenfl/flFoxp3-Cre 
mice largely accounts for the exacerbated TFH, GC, and autoimmune responses, thereby 
highlighting the crucial role of PTEN signaling in Treg cells to coordinate TH1 and TFH 
reactions.  
 
 
PTEN Is Crucial in Maintaining the Stability of Treg Cells 
 
Despite the crucial role of IFN-? overproduction in disrupting immune 
homeostasis in Ptenfl/flFoxp3-Cre mice, deletion of IFN-? did not affect the phenotype of 
increased Treg cellularity in these mice (Figure 3-21A). We therefore explored the direct 
effects of Pten deficiency on the homeostasis and functionality of Treg cells. As 
compared with WT counterparts, Treg cells from Ptenfl/flFoxp3-Cre mice showed higher 
expression of CD44 and CD69 but lower levels of CD62L, indicating an elevated level of 
activation (Figure 3-22A). We next examined Treg-selective effector molecules. 
Ptenfl/flFoxp3-Cre Treg cells showed increased levels of ICOS and PD-1, and to a lesser 
extent, GITR, whereas the expression of CTLA4 was largely normal (Figure 3-22B). In 
sharp contrast to the elevated expression of activation markers and effector molecules, 
the expression of CD25, a signature molecule of Treg and activated T cells, was 
markedly downregulated in Ptenfl/flFoxp3-Cre Treg cells, corresponding to the expansion 
of the Foxp3+CD25– population (Figure 3-22C). As compared with Foxp3+CD25+ cells, 
the Foxp3+CD25– population expressed lower levels of Foxp3, as reported previously 
(Komatsu et al., 2009). Consistent with this observation, Blimp1, a transcription factor 
implicated in CD25 downregulation in CD8+ T cells (Shin et al., 2013), was upregulated 
in Ptenfl/flFoxp3-Cre Treg cells (Figure 3-22D). These results indicate that Pten 
deficiency in Treg cells results in dysregulated expression of multiple Treg activation and 
phenotypic molecules. 
 
The lineage stability of Treg cells is a matter of considerable interest and debate 
(Bailey-Bucktrout et al., 2013; Komatsu et al., 2014; Miyao et al., 2012; Rubtsov et al., 
2010; Tsuji et al., 2009; Zhou et al., 2009b), but the signaling mechanisms involved are 
largely unexplored. To determine whether Pten deficiency affects the stability of Treg 
 53 
 
 
Figure 3-16. Generation and phenotypic analysis of Ptenfl/flFoxp3-Cre Ifng–/– mice. 
Cytokine production of (A) IFN-γ, (B) IL-17 and (C) IL-4 by CD4+ T cells from WT, 
Ptenfl/flFoxp3-Cre, Ifng–/– and Ptenfl/flFoxp3-Cre Ifng–/– mice after in vitro stimulation for 
4 h with PMA plus ionomycin in the presence of monensin. Numbers indicate percentage 
of cells in quadrants or gates. 
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Figure 3-17. Uncontrolled TFH and GC B cells in Ptenfl/flFoxp3-Cre mice rescued in 
Ptenfl/flFoxp3-Cre Ifng–/– mice. 
Analysis of (A) TFH and (B) GC B cells in the spleen of WT, Ptenfl/flFoxp3-Cre, Ifng–/– 
and Ptenfl/flFoxp3-Cre Ifng–/– mice. Numbers indicate percentage of cells in quadrants or 
gates. 
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Figure 3-18. Immunochistochemistry of germinal centers in WT, Ptenfl/flFoxp3-Cre, Ifng–/– and Ptenfl/flFoxp3-Cre Ifng–/– mice. 
(A) PNA staining of spleen sections (magnification, x2; scale bars, 2mm) and (B) immunofluorescence and quantification of MLN 
sections for the staining of CD3 (red), PNA (green) and IgD (white) (scale 500 μm) from WT, Ptenfl/flFoxp3-Cre, Ifng–/– and 
Ptenfl/flFoxp3-Cre Ifng–/– mice. 
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Figure 3-19. Detection of antinuclear antibodies in WT, Ptenfl/flFoxp3-Cre, Ifng–/– and Ptenfl/flFoxp3-Cre Ifng–/– mice. 
Representative images and quantification of fluorescent intensity of ANA IgG autoantibodies detected with Hep-2 slides in the serum 
from WT, Ptenfl/flFoxp3-Cre, Ifng–/– and Ptenfl/flFoxp3-Cre Ifng–/– mice. (Scale 60 μm). 
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Figure 3-20. Immunofluorescence analysis of glomeruli for IgG deposits in WT, Ptenfl/flFoxp3-Cre, Ifng–/– and Ptenfl/flFoxp3-
Cre Ifng–/– mice.   
Representative images of immunofluorescence imaging of kidney sections showing IgG deposits (scale 300 μm), and quantitative 
analysis (right) from WT, Ptenfl/flFoxp3-Cre, Ifng–/– and Ptenfl/flFoxp3-Cre Ifng–/– mice. 
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Figure 3-21. Analysis of Treg cells in WT, Ptenfl/flFoxp3-Cre, Ifng–/– and 
Ptenfl/flFoxp3-Cre Ifng–/– mice.   
Flow cytometry analysis of (A) Treg (CD4+Foxp3+) cells and expression of (B) CD25 
and Foxp3 (gated on CD4+TCRβ+ cells) in the spleen of WT, Ptenfl/flFoxp3-Cre, Ifng–/– 
and Ptenfl/flFoxp3-Cre Ifng–/– mice. Numbers indicate percentage of cells in gates. 
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Figure 3-22. Effects of Pten loss in Treg cells.  
(A) Expression of CD44, CD69 and CD62L and (B) ICOS, PD-1, GITR and CTLA4 in 
Treg cells from the spleen of WT and Ptenfl/flFoxp3-Cre mice, with mean fluorescence 
intensity (MFI) plotted above graphs. (C) Expression of CD25 and Foxp3 (gated on 
CD4+TCRβ+ cells) in the spleen of WT and Ptenfl/flFoxp3-Cre mice; numbers above 
graphs indicate MFI of Foxp3 in CD25− and CD25+ subsets. Right, quantification of 
Foxp3+CD25− cells. Numbers indicate percentage of cells in quadrants or gates.  (D) 
Expression of Blimp1 in splenic Treg cells of WT and Ptenfl/flFoxp3-Cre mice. Numbers 
above graphs indicate MFI of Blimp1. **P < 0.001. Data are mean ± s.e.m.  
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cells, we crossed Ptenfl/flFoxp3-Cre mice with a Cre recombination-sensitive reporter 
allele, in which the ubiquitously expressed ROSA26 locus contains a loxP site–flanked 
STOP cassette followed by the gene encoding green fluorescent protein (GFP) (Zeng et 
al., 2013). In this lineage tracing system, Foxp3-Cre-mediated excision of the floxed 
STOP cassette results in constitutive, heritable expression of GFP, even for those “ex-
Treg” cells that have lost Foxp3 expression (the GFP+YFP-Foxp3– population). 
Ptenfl/flFoxp3-Cre mice contained a notable accumulation of the GFP+YFP-Foxp3– 
population (Figure 3-23A), indicating the preferential loss of Foxp3 expression upon 
Pten deletion. Additionally, Treg cells from Ptenfl/flFoxp3-Cre mice had increased 
expression of IFN-?, whereas IL-17 expression was largely unaltered  
(Figure 3-24A and B).  
 
Moreover, Pten-deficient Treg cells upregulated signature molecules 
characteristic of TH1 and TFH cells, including CXCR3 and T-bet, and CXCR5 and Bcl6, 
respectively, whereas expression of IRF4 and p-STAT3, which are required for Treg cell-
mediated suppression of TH2 and TH17 cells (Chaudhry et al., 2009; Zheng et al., 2009), 
remained unchanged (Figure 3-24C) Consistent with these observations, Pten-deficient 
Treg cells contained an expanded T-bet+CXCR3+ population that is important for the 
regulation of type 1 inflammation (Figure 3-24D) (Koch et al., 2009). Because the 
development of this Treg cell subset is dependent upon IFN-? signaling (Koch et al., 
2009), we examined whether excessive IFN-? production in Ptenfl/flFoxp3-Cre mice was 
involved in the dysregulation of T-bet and CXCR3. IFN-? deficiency had a partial rescue 
effect on the expansion of T-bet+CXCR3+ population in Pten-deficient Treg cells  
(Figure 3-24D), indicating that the augmented expression of T-bet and CXCR3 upon loss 
of Pten is largely cell intrinsic, not simply secondary to the overproduction of IFN-?. 
Finally, to directly test the role of PTEN in maintaining Treg stability, we sorted 
Foxp3+CD25+ cells from WT and Ptenfl/flFoxp3-Cre mice and transferred them into 
congenic mice (CD45.1+). The expression of Foxp3 and CD25 was downregulated in 
Pten-deficient Treg cells in various organs examined, as compared with WT cells 
(Figure 3-23B and C). These complementary approaches indicate that Pten deficiency 
results in a loss of Treg stability. 
 
Notably, despite the strong effects of IFN-? at disrupting immune homeostasis, 
deletion of IFN-? in Ptenfl/flFoxp3-Cre mice did not affect the spontaneous development 
of the Foxp3+CD25– population (Figure 3-21B). Thus, the enhanced IFN-? expression 
from Pten-deficient Treg cells is associated with the loss of Treg cell stability, but this 
cytokine is unlikely to be the main driver of instability.   
 
 
PTEN Is Haploinsufficient in Treg Cells 
 
Given the potent effects of PTEN signaling in Treg cells, we asked whether 
partial loss of PTEN function in Treg cells is physiologically relevant, by analyzing 
Ptenfl/+Foxp3-Cre mice. As expected, Ptenfl/+Foxp3-Cre Treg cells, but not other T cell 
subsets, had partial reduction of PTEN expression at both the mRNA and protein levels 
(Figure 3-25A and B). Remarkably, heterozygous loss of Pten resulted in the expansion 
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Figure 3-23. Pten deficiency impairs Treg cell stability. 
(A) Foxp3-YFP and GFP expression in CD4+ T cells from Pten+/+Foxp3-
Cre Rosa26GFP and Ptenfl/flFoxp3-Cre Rosa26GFP mice. (B) Left, donor cell percentages 
(top) and Foxp3 and CD25 expression (bottom) in WT and Ptenfl/flFoxp3-Cre 
Treg (CD45.2+) cells transferred into CD45.1+ recipients. Right, expression of Foxp3 and 
CD25 from donor-derived WT and Ptenfl/flFoxp3-Cre T cells; numbers above graphs 
indicate MFI. (C) Analysis of Foxp3 (top) and CD25 (bottom) expression in PLNs and 
MLNs of CD45.1+ recipients after transferring WT and Ptenfl/flFoxp3-Cre Treg (CD45.2+) 
cells. Numbers above graphs indicate MFI. Numbers indicate percentage of cells in 
quadrants or gates. 
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Figure 3-24. Analysis of Treg cells in Ptenfl/flFoxp3-Cre Ifng−/− mice and 
Ptenfl/flFoxp3-Cre Treg cell phenotypes under steady state. 
(A) Expression of IFN-γ and IL-17 (right, quantification of IFN-γ+ and IL-17+ producing 
cells in Treg cells) (B) Analysis of Ifng RNA in Treg cells of WT and Ptenfl/flFoxp3-Cre 
mice. (C) Expression of CXCR3, CXCR5, T-bet, Bcl6, IRF4 and p-Stat3 in Treg cells 
from the spleen of WT and Ptenfl/flFoxp3-Cre mice. (D) Analysis of CXCR3 and T-bet 
expression in Treg cells in the spleen of WT, Ptenfl/flFoxp3-Cre, Ifng−/− and 
Ptenfl/flFoxp3-Cre Ifng−/− mice. Data are mean ± s.e.m. *P < 0.05 and **P < 0.001. 
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Figure 3-25. Pten expression and immune dysregulation in Ptenfl/+Foxp3-Cre mice. 
Analysis of (A) Pten mRNA and (B) protein expression in Treg, naïve CD4+ 
(CD62L+CD44−), and CD8+ T cells from WT and Ptenfl/+Foxp3-Cre mice. Numbers 
below the PTEN lanes in (B) indicate band intensity relative to that of β-actin. (C) 
Immunofluorescence of spleen sections of WT and Ptenfl/+Foxp3-Cre mice for the 
staining of CD3 (red) and PNA (green) showing germinal center (scale 60 μm). Right, 
quantification of germinal center area. (D) Images of peripheral lymph nodes from WT 
and Ptenfl/+Foxp3-Cre mice (~5 months old) with lymphoproliferative disease. Data are 
mean ± s.e.m. *P < 0.05. 
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of Treg cells, associated with the considerable downregulation of CD25 expression 
(Figure 3-26A). Ptenfl/+Foxp3-Cre mice also showed a notable accumulation of 
GFP+YFP-Foxp3– population in the lineage tracing system (Figure 3-26B). Moreover, 
these mice had higher frequencies of CXCR5+PD-1+ TFH cells and GL7+CD95+ GC B 
cells (Figure 3-26C), and a greater abundance of GCs in the spleen (Figure 3-25C). 
These findings prompted us to examine whether heterozygous loss of Pten in Treg cells 
caused autoimmunity and lymphoid hyperplasia as observed in Ptenfl/flFoxp3-Cre mice. 
Ptenfl/+Foxp3-Cre mice displayed significantly elevated titers of circulating ANA 
antibodies (Figure 3-27) and augmented IgG deposits in the kidney glomeruli  
(Figure 3-28), indicative of systemic autoimmunity. Furthermore, Ptenfl/+Foxp3-Cre 
mice spontaneously developed lymphoadenopathy (Figure 3-25D). These results 
demonstrate that PTEN is haploinsufficient in Treg cells. 
 
 
Summary 
 
In this chapter, we used conditional knockout mice with Pten specifically deleted 
in Treg cells to explore its functional relevance in vivo. We have highlighted Treg-
specific loss of Pten results in higher frequency of activated CD44hi T cells and Treg 
cells. Additionally, excessive TFH responses (CXCR5+PD1+CD4+ T cells) and 
spontaneous formation of germinal centers (detected with PNA staining and 
immunofluorescence assay) was also seen in steady state. Increased TFH and germinal 
center reactions were also evident in Ptenfl/flFoxp3-Cre after using SRBC or NP-OVA 
immunization. Loss of Pten in Treg cells was sufficient to induce the development of 
systemic autoimmune and lymphoproliferative disease, as determined by histological 
analyses, autoantibody (dsDNA and ANA) detection, and immunofluorescence of IgG 
deposits in kidney. Furthermore, deletion of IFN-? considerably blocked such immune 
dysregulation, indicating the coordinated control of TH1 and TFH responses by PTEN 
signaling in Treg cells (investigated using Ptenfl/flFoxp3-Cre Ifng–/– double knockout 
mice). Using lineage tracing and in vivo transfer models, we elucidated the underlying 
mechanisms by showing that deletion of Pten resulted in instability of Treg cells, featured 
by decreased expression of CD25 and Foxp3 expression. Finally, we presented evidence 
that PTEN is haploinsufficient in Treg cells. Together, the findings shown in this chapter 
have established the necessity of PTEN signaling in Treg cells for normal immune 
tolerance. 
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Figure 3-26. Heterozygous loss of Pten in Treg cells is sufficient to disrupt immune homeostasis. 
(A) Flow cytometry analysis of Foxp3 and CD25 expression in WT and Ptenfl/+Foxp3-Cre splenic CD4+ T cells. (B) Foxp3-YFP and 
GFP expression in CD4+ T cells from Pten+/+Foxp3-Cre Rosa26GFP and Ptenfl/+Foxp3-Cre Rosa26GFP mice. (C) Analysis of 
CXCR5+PD-1+ cells (gated on CD4+TCRβ+ cells) and GL7+CD95+ GC B cells (gated on CD19+ B cells) in the spleen of WT and 
Ptenfl/+Foxp3-Cre mice. Numbers indicate percentage of cells in gates. 
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Figure 3-27. Detection of antinuclear antibodies in WT and Ptenfl/+Foxp3-Cre mice. 
Representative images (scale bars, 60 μm) and quantification of fluorescent intensity (right) of serum anti-ANA IgG detected with 
fixed Hep-2 slides in WT and Ptenfl/+Foxp3-Cre mice. Data are mean ± s.e.m. *P < 0.001. 
 
 
 
 
 
 
 67 
 
Figure 3-28. Immunofluorescence analysis of glomeruli for IgG deposits in WT and Ptenfl/+Foxp3-Cre mice. 
Immunofluorescence (left) and quantification (right) of IgG deposits in kidney glomerulus sections (scale bars, 100 μm) from WT and 
Ptenfl/+Foxp3-Cre mice. Data are mean ± s.e.m. *P < 0.0001. 
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CHAPTER 4.    MOLECULAR AND METABOLIC MECHANISMS OF PTEN 
SIGNALING* 
 
 
In this chapter, we aimed to characterize the mechanisms underlying Pten-
deficient Treg cell dysfunction and stability described in Chapter 3. Mechanistically, Pten 
deficiency results in dysregulated transcriptional and metabolic programs, including the 
balance between glycolytic activity and mitochondrial fitness. Further, mTORC2, not 
mTORC1 activity, is upregulated by Pten deletion in Treg cells. Depletion of Rictor-
mTORC2 activity is sufficient to restore the functional abnormalities observed in Pten-
deficient Treg cells. Additionally, retention of mTORC2 downstream target Foxo1 in the 
nucleus seems to abrogate the effects of PTEN loss in Treg cells. Our studies presented in 
this chapter establish a crucial role of the PTEN-mTORC2 axis in mediating Treg cell 
stability and homeostasis of the immune system. 
 
 
PTEN-dependent Transcriptional and Metabolic Programs in Treg Cells 
 
To explore PTEN-dependent molecular mechanisms in Treg cells, we next used 
microarrays to compare the transcriptional profiles between WT and Ptenfl/flFoxp3-Cre 
Treg cells. Ptenfl/flFoxp3-Cre Treg cells contained a total of 498 probes (representative of 
352 unique genes) with a greater than 1.5-fold difference, including 212 upregulated and 
286 downregulated probes. Principal component analysis (PCA) showed the clear 
distinctions between WT and Ptenfl/flFoxp3-Cre samples (Figure 4-1A). Consistent with 
the dysregulated stability, loss of Pten failed to restrain the transcription of genes 
involved in TFH differentiation, including Gzmb, Il21, Bcl6, Pdcd1, Il4, Maf and Cxcr5 
(Crotty, 2011; Wang et al., 2014) (Figure 4-2). To identify key networks regulated by 
PTEN, we performed gene-set enrichment analysis (GSEA) (Subramanian et al., 2005) to 
compare gene expression profiles of WT and Pten-deficient Treg cells. Remarkably, the 
top-ten, upregulated gene-sets in Ptenfl/flFoxp3-Cre Treg cells were all associated with 
cell cycle pathways (Figure 4-1B and C). To examine PTEN-dependent canonical 
pathways in Treg cells, we next performed the ingenuity pathway analysis (IPA) system 
by interrogating the differentially expressed genes at the 1.5-fold cut-offs. As shown in 
Figure 4-3, Pten deficiency affected multiple canonical pathways implicated in 
autoimmune diseases, helper T cell differentiation, and immune signaling mediated by 
transcription factors, co-stimulatory molecules and cytokines. Gene ontology (GO) 
analysis of these differentially regulated genes also showed that Pten-deficient Treg cells 
significantly upregulated groups of genes involved in autoimmune diseases, such as 
autoimmune thyroid disease and SLE, as well as in cell cycle regulation (Supplementary 
Data 1 – Gene Ontology Analysis of Pten-deficient Treg Mice). The transcriptome 
analysis therefore highlights an important role of PTEN in the regulation of immune 
response and cell cycle pathways. 
------------------------ 
*Chapter 4 reprinted with permission. Shrestha, S., Yang, K., Guy, C., Vogel, P., Neale, 
G., and Chi, H. (2015). Treg cells require the phosphatase PTEN to restrain TH1 and TFH 
cell responses. Nature immunology 16, 178-187.  
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Figure 4-1. The transcriptional profiles controlled by Pten in Treg cells. 
(A) PCA mapping of WT and Ptenfl/flFoxp3-Cre Treg cells. (B) GSEA reveals the cell 
cycle mitotic pathway as one of the most extensively upregulated pathways in 
Ptenfl/flFoxp3-Cre Treg cells. (C) The list of top 10 gene sets upregulated in 
Ptenfl/flFoxp3-Cre Treg cells by GSEA. NES, normalized enrichment score. 
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Figure 4-2. PTEN-dependent gene expression analysis. 
Heat map of expression of TFH genes related upregulated in Ptenfl/flFoxp3-Cre mice, 
relative to the WT mean (≥1.5-fold). 
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Figure 4-3. Ingenuity pathway analysis (IPA) of the differentially expressed genes 
in Ptenfl/flFoxp3-Cre Treg cells. 
IPA of canonical pathways controlled by Pten in Treg cells, differentially expressed 
genes at the 1.5-fold cut-offs. 
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Cellular metabolic programs, especially glycolysis and mitochondrial oxidative 
phosphorylation, play an important role in shaping Treg cell generation and function 
(Michalek et al., 2011a; Shi et al., 2011), although the molecular mechanisms are 
unknown. As compared with WT Treg cells, Pten-deficient Treg cells more strongly 
upregulated glycolysis after TCR/CD28 stimulation (Figure 4-4A). We next examined 
whether Pten deficiency affects mitochondrial fitness by measuring multiple parameters 
associated with mitochondria homeostasis and functions. Pten-deficient Treg cells 
showed considerable reductions of reactive oxidative species (ROS), mitochondrial mass, 
and mitochondrial membrane potential, indicative of impaired mitochondrial fitness 
(Figure 4-4B). Notably, the reductions of these parameters was more prominent in Pten-
deficient Foxp3+CD25– Treg cells than Foxp3+CD25+ Treg cells (Figure 4-4B), 
indicating that impaired mitochondrial function is associated with Treg cell instability. 
Moreover, the Foxp3+CD25– Treg subset had modestly increased BrdU incorporation 
than Foxp3+CD25+ cells (Figure 4-4C). Altogether, these data establish that PTEN 
signaling links immune response gene expression, cell cycle progression, and metabolic 
balance between glycolytic activity and mitochondrial fitness in Treg cells. 
 
PTEN Restrains mTORC2 Activity in Treg Cells 
 
We next determined PTEN-dependent biochemical mechanisms in Treg cells by 
examining mTORC1 and mTORC2 activities, as both are under the control of PTEN in 
multiple cell types (Chi, 2012). In response to short-term anti-CD3-CD28 stimulation (5-
15 min), Ptenfl/flFoxp3-Cre Treg cells exhibited slightly elevated phosphorylation of the 
mTORC1 target S6, as compared with WT Treg cells (Figures 4-5A and 4-6A). In 
contrast, Ptenfl/flFoxp3-Cre Treg cells exhibited much stronger activation of mTORC2 
signaling than WT cells, as indicated by the enhanced phosphorylation of AKT at Ser473 
and of the AKT substrate, Foxo1 (Figure 4-5A). We next determined the effects of 
stimulating Treg cells with anti-CD3-CD28 for a longer time (20 h), in the presence or 
absence of IL-2. Both WT and Pten-deficient Treg cells responded to these stimuli with 
robust phosphorylation of S6 and 4EBP1, indicative of comparable activation of the 
mTORC1 pathway under these conditions (Figures 4-5B and 4-6B). In contrast, 
Ptenfl/flFoxp3-Cre Treg cells exhibited much stronger activation of mTORC2 signaling 
than WT cells (Figure 4-5B). Therefore, loss of PTEN results in preferential activation of 
mTORC2 signaling in Treg cells. 
 
To determine the contribution of mTORC2 activity to the phenotypes of 
Ptenfl/flFoxp3-Cre mice, we generated mice bearing Treg cells with a double deletion of 
Pten and the mTORC2 obligate adaptor Rictor (termed Ptenfl/flRictorfl/flFoxp3-Cre mice), 
since Rictor is an essential regulator of mTORC2 activity in Treg cells (Zeng et al., 
2013). In contrast to the phenotype observed in Ptenfl/flFoxp3-Cre mice, Treg cells in 
Ptenfl/flRictorfl/flFoxp3-Cre mice exhibited normal abundance and CD25 expression 
(Figure 4-7). Other Treg cell markers analyzed were also considerably rescued by the 
deletion of Rictor from Ptenfl/flFoxp3-Cre Treg cells (Figure 4-8A). Additionally, T cells 
in Ptenfl/flRictorfl/flFoxp3-Cre mice exhibited largely normal distribution of naïve and 
effector/memory phenotypes (Figure 4-8B). Also, the spontaneous development of TFH 
and TH1 cells and GC B cells observed in Ptenfl/flFoxp3-Cre mice was blocked by 
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Figure 4-4. PTEN-dependent metabolic programs in Treg cells. 
(A) Glycolytic activity of Treg cells stimulated with α-CD3-CD28. (B) ROS production, 
mitochondrial mass and mitochondrial membrane potential in Treg cells of WT and 
Ptenfl/flFoxp3-Cre mice. Numbers above graphs indicate mean fluorescence intensity 
(MFI). (C) BrdU incorporation in Treg subsets of WT and Ptenfl/flFoxp3-Cre mice. 
Numbers indicate percentage of cells in gates. 
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Figure 4-5. Dysregulation of mTORC2 activity in Pten-deficient Treg cells. 
Immunoblot analysis of (A) p-Akt(S473), p-Foxo1 and p-S6 in resting and short-term–
stimulated and (B) long-term–stimulated Treg cells isolated from WT and Ptenfl/flFoxp3-
Cre mice. 
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Figure 4-6. Analysis of Pten expression in short and long term stimulated Treg 
cells.  
(A) Pten expression in resting and short-term stimulated Treg cells and (B) 
phosphorylation of 4E-BP1 and Pten in resting and long-term stimulated Treg cells 
isolated from WT and Ptenfl/flFoxp3-Cre mice.  
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Figure 4-7. Analysis of Treg cells in Ptenfl/flFoxp3-Cre and Ptenfl/flRictorfl/flFoxp3-
Cre mice under steady state. 
Flow cytometry analysis of WT, Ptenfl/flFoxp3-Cre, Rictorfl/flFoxp3-Cre and 
Ptenfl/flRictorfl/flFoxp3-Cre mice for (A) Foxp3 and (B) CD25 expression in CD4+ T cells. 
Numbers indicate percentage of cells in gates. 
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Figure 4-8. Pten represses mTORC2 signaling in Treg cells to maintain immune homeostasis. 
(A) Expression of CD69, CD62L, CXCR5, ICOS and PD-1, and measurements of ROS, mitochondrial mass, and mitochondrial 
membrane potential (TMRM) in Treg cells from the spleen of WT, Ptenfl/flFoxp3-Cre, Rictorfl/flFoxp3-Cre and Ptenfl/flRictorfl/flFoxp3-
Cre mice. (B) Flow cytometry analysis of WT, Ptenfl/flFoxp3-Cre, Rictorfl/flFoxp3-Cre and Ptenfl/flRictorfl/flFoxp3-Cre mice for CD62L 
and CD44 expression on CD4+ and CD8+ T cells and, (C) cytokine production of CD4+ T cells.  
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Rictor deletion (Figures 4-9 and 4-8C). Moreover, unlike Ptenfl/flFoxp3-Cre mice, 
Ptenfl/flRictorfl/flFoxp3-Cre mice did not contain IgG deposits in the kidney glomeruli 
(Figure 4-10), and exhibited normal GC numbers in the spleen and MLNs  
(Figure 4-11A and B). Therefore, despite the plethora of pathways identified to mediate 
PTEN functions in various cells (Chi, 2012), PTEN acts in a mTORC2-dependent 
manner in Treg cells to impinge upon immune homeostasis and tolerance.  
 
 
Nuclear Retention of Foxo1 Abrogates the Effects of PTEN Loss 
 
 Activation of AKT by mTORC2 leads to phosphorylation of transcription factor 
Foxo1 that interacts with Foxp3 and is critical for Treg cell lineage maintenance (Harada 
et al., 2010; Kerdiles et al., 2010; Ouyang et al., 2009; Ouyang et al., 2010; Ouyang et al., 
2012). To determine the contribution of mTORC2-AKT-mediated inhibition of Foxo1 
activity t to the phenotypes of Ptenfl/flFoxp3-Cre mice, we crossed Ptenfl/flFoxp3-Cre 
mice with those expressing the one allele of Foxo1AAA mutant to generate Ptenfl/fl 
Foxo1AAA/+Foxp3-Cre. This mutant is constitutively localized to the nucleus, as it lacks 
the inhibitory AKT phosphorylation sites (Ouyang et al., 2012). Importantly, the 
Foxo1AAA heterozygous mice were selected for analysis, as homozygous mice are prone 
to wasting disease (Luo et al., 2016). 
  
In preliminary experiments, ectopic expression of Foxo1AAA ameliorated several 
phenotypic characteristics, such as the altered distribution of naive and effector or 
memory and increased IFN-γ production seen in T cells from Ptenfl/flFoxp3-Cre mice 
(Figure 4-12A and B). Additionally, expression of Foxo1AAA substantially dampened the 
aberrant TFH and GC B cell responses of Ptenfl/flFoxp3-Cre mice (Figure 4-13). 
Moreover, no visible lymphadenopathy (unpublished observations) and rectified ANA 
levels (Figure 4-14), indicates absence of lymphoproliferative disease in Ptenfl/fl 
Foxo1AAA/+Foxp3-Cre mice. Interestingly, the high frequency of CD4+YFP+ and CD25-
YFP+ Treg cells were still seen in Ptenfl/fl Foxo1AAA/+Foxp3-Cre mice (Figure 4-15). 
Therefore, despite Foxo1 being a downstream target of mTORC2-AKT, the data 
presented above indicates alternative downstream targets control Treg cell cellularity and 
stability, which needs to be further studied. 
 
 
Summary 
 
 In this chapter, we highlighted PTEN orchestrates transcriptional programs and 
the metabolic balance between glycolysis and mitochondrial fitness to support Treg cell 
function. Phenotypic observations of abnormalities we characterized in Chapter 3 due 
were attributed to dysregulated activation of the mTORC2-mediated pathway, as 
generation of Ptenfl/flRictorfl/flFoxp3-Cre mice ameliorated those defects. Further, these 
defects were linked to excessive inactivation of Foxo1, because expression of the AKT-
insensitive FoxoAAA mutant also alleviated several features of disease seen in 
Ptenfl/flFoxp3-Cre mice. However, the higher frequency and instability of Treg cells still 
remained consistent, which indicated involvement of additional alternative targets  
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Figure 4-9. Analysis of TFH and GC B cells in Ptenfl/flFoxp3-Cre and 
Ptenfl/flRictorfl/flFoxp3-Cre mice under steady state. 
Flow cytometry analysis of WT, Ptenfl/flFoxp3-Cre, Rictorfl/flFoxp3-Cre and 
Ptenfl/flRictorfl/flFoxp3-Cre mice for proportions of (A) TFH cells in CD4+ T cells and (B) 
GC B cells in total B cells. Numbers indicate percentage of cells in gates. 
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Figure 4-10. Immunofluorescence analysis of glomeruli for IgG deposits in WT, Ptenfl/flFoxp3-Cre, Rictorfl/flFoxp3-Cre and 
Ptenfl/flRictorfl/flFoxp3-Cre mice. 
Imaging (left) and quantification (right) of IgG deposits in kidney sections of WT, Ptenfl/flFoxp3-Cre, Rictorfl/flFoxp3-Cre and 
Ptenfl/flRictorfl/flFoxp3-Cre mice (scale bars, 300 μm). 
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Figure 4-11. Immunochistochemistry of germinal centers in WT, Ptenfl/flFoxp3-Cre, Rictorfl/flFoxp3-Cre and 
Ptenfl/flRictorfl/flFoxp3-Cre mice. 
(A) PNA staining of spleen sections (magnification, x2; scale bars, 2mm) and (B) immunofluorescence and quantification of MLN 
sections for the staining of CD3 (red), PNA (green) and IgD (white) (scale 500 μm) from WT, Ptenfl/flFoxp3-Cre, Rictorfl/flFoxp3-Cre 
and Ptenfl/flRictorfl/flFoxp3-Cre mice. 
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Figure 4-12. Analysis of Ptenfl/flFoxp3-Cre and Ptenfl/fl Foxo1AAA/+Foxp3-Cre mice 
under steady state. 
(A) Flow cytometry analysis of WT, Ptenfl/flFoxp3-Cre, Foxo1AAA/+Foxp3-Cre and 
Ptenfl/fl Foxo1AAA/+Foxp3-Cre mice for CD62L and CD44 expression on CD4+ and CD8+ 
T cells and, (B) IFN-γ production of by CD4+ and CD8+ T cells.  
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Figure 4-13. Analysis of TFH and GC B cells in Ptenfl/flFoxp3-Cre and Ptenfl/fl 
Foxo1AAA/+Foxp3-Cre mice under steady state. 
Flow cytometry analysis of WT, Ptenfl/flFoxp3-Cre, Foxo1AAA/+Foxp3-Cre and Ptenfl/fl 
Foxo1AAA/+Foxp3-Cre mice for proportions of (A) TFH cells in CD4+ T cells and (B) GC 
B cells in total B cells. Numbers indicate percentage of cells in gates. 
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Figure 4-14. Detection of antinuclear antibodies in WT, Ptenfl/flFoxp3-Cre, Foxo1AAA/+Foxp3-Cre and Ptenfl/fl 
Foxo1AAA/+Foxp3-Cre mice. 
Representative images (scale bars, 50 μm) and quantification of fluorescent intensity (right) of serum anti-ANA IgG detected with 
fixed Hep-2 slides in WT, Ptenfl/flFoxp3-Cre, Foxo1AAA/+Foxp3-Cre and Ptenfl/fl Foxo1AAA/+Foxp3-Cre mice.  
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Figure 4-15. Analysis of Treg cells in Ptenfl/fl Foxo1AAA/+Foxp3-Cre mice under 
steady state. 
Flow cytometry analysis of WT, Ptenfl/flFoxp3-Cre, Foxo1AAA/+Foxp3-Cre and Ptenfl/fl 
Foxo1AAA/+Foxp3-Cre mice for (A) Foxp3 and (B) CD25 expression in CD4+ T cells. 
Numbers indicate percentage of cells in gates. 
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downstream of mTORC2-AKT pathway for Treg cell programming. To summarize, we 
have established a new paradigm that the interplay between immune signaling and 
metabolic activity links Treg cell stability. At the molecular levels, PTEN orchestrates 
Treg stability and functional diversity by impinging upon the metabolic balance and 
mTORC2 signaling. 
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CHAPTER 5.    DISCUSSION* 
 
 
Much emphasis has been placed on the transcriptional and molecular pathways 
underlying effector T cell diversity and plasticity (Zhu et al., 2010). In contrast, how 
these distinct effector T cell responses are controlled by extrinsic mechanisms is poorly 
understood. Moreover, despite the emerging evidence for the adoption of TH-specific 
transcription factors by Treg cells to suppress the corresponding effector responses 
(Chaudhry et al., 2009; Koch et al., 2009; Zheng et al., 2009), we have little 
understanding about the signaling mechanisms in Treg cells that program and coordinate 
these suppressive activities. Our studies identify PTEN as an important molecular 
pathway in Treg cells that coordinately regulates TFH and TH1 responses (Figure 5-1). 
Our findings are consistent with the results reported by our colleagues, Huynh et al. 
(Huynh et al., 2015). In particular, loss of Pten in Treg cells results in exacerbated TFH 
and GC responses and the loss of immune tolerance and tissue homeostasis. Using 
genetic approaches to ablate IFN-? function, we have revealed the hierarchy between 
Treg cell-mediated control of TH1 and TFH responses, with the production of the TH1 
signature cytokine IFN-? a prerequisite for the potentiation of TFH responses 
Ptenfl/flFoxp3-Cre mice. Furthermore, the repression of TH1 and TFH responses is 
associated with the active maintenance of Treg cell stability mediated by PTEN 
signaling. At the molecular levels, PTEN controls the transcriptional program and 
metabolic balance in Treg cells, and signals mainly via inhibition of mTORC2 activity. 
Further, our data suggests PTEN-dependent mTORC2 inhibition is important to maintain 
the appropriate balance of Foxo1 function in Treg cells. Our studies therefore establish 
that the PTEN-mTORC2 signaling axis acts as a central pathway to enforce Treg cell 
stability and further links it to the control of TH1 and TFH responses. Loss of this control 
mechanism is detrimental to immune homeostasis and tolerance, highlighting the 
physiological significance of this new control mechanism. 
 
The lineage stability of Treg cells remains contentious (Bailey-Bucktrout et al., 
2013; Komatsu et al., 2009; Komatsu et al., 2014; Miyao et al., 2012; Rubtsov et al., 
2010; Tsuji et al., 2009; Zhou et al., 2009b) but is an issue of utmost importance, as it 
directly impinges upon Treg cell-mediated control of health and disease and therapeutic 
strategies (Sakaguchi et al., 2013). Part of the controversies stem from the limited 
understanding of the underlying molecular processes, despite the extensive research on 
the regulation of Foxp3 itself. Using lineage tracing and adoptive transfer systems, we 
show that Pten-deficient Treg cells are more prone to lose Foxp3 expression in vivo. 
However, Pten deficiency results in apparently hyper-activated Treg cells, as evidenced 
by increased cycling, upregulation of activation and phenotypic markers, and 
dysregulated expression of IFN-? and other TH1 and TFH signature molecules. Consistent  
 
 
------------------------ 
*Chapter 5 reprinted with permission. Shrestha, S., Yang, K., Guy, C., Vogel, P., Neale, 
G., and Chi, H. (2015). Treg cells require the phosphatase PTEN to restrain TH1 and TFH 
cell responses. Nature immunology 16, 178-187. 
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Figure 5-1. Schematics of PTEN signaling in Treg cell functions and immune tolerance. 
Loss of PTEN in Treg cells dysregulates mTORC2 signaling and metabolic and transcriptional programs, leading to the disrupted 
stability of Treg cells (as evidenced by the downregulation of CD25 expression, as well as other abnormalities not depicted here). 
Associated with loss of Treg cell stability and the ensuing TH1 responses and IFN-? production is the aberrant induction of TFH 
responses, spontaneous formation of germinal center responses, and development of autoimmune and lymphoproliferative disease. 
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with the hyper-activation of Treg cells, Pten deletion results in marked loss of CD25 
expression, which is normally downregulated in Treg cells after in vivo activation and 
proliferation (Gavin et al., 2002). 
 
While representing only a minor proportion of Foxp3+ Treg cells under steady 
state, the Foxp3+CD25– population likely makes an important contribution, via 
conversion or selection, to the generation of ex-Treg cells under inflammatory or 
lymphopenic environment. Therefore, our studies highlight that the stability of Treg cells 
under steady state requires active enforcement by PTEN, which functions, at least in part, 
by preventing overt Treg cell activation and CD25 downregulation. 
 
Both mTOR complexes plays an important role in maintenance of Treg cells, as 
dysregulated mTORC1 signaling results in unstable Treg cells giving rise to TH17-like 
effector T cells (Park et al., 2013), suggesting a dominant role of the PI3K-PDK1 
pathway on Treg stability and function (Wei et al., 2016). Our results showing instability 
of Treg cells and phenotypes associated with TH1 cells due to loss of PTEN is mTORC2-
mediated. As PIP3 has been linked to direct activation of mTORC2 (Gan et al., 2011; Liu 
et al., 2015), the results we obtained seem to be independent of PDK1-associated 
activation. 
 
The generation of TFH cells, the specialized providers of help to B cells, requires 
unique transcriptional programs and is antagonized by TFR cells (Chung et al., 2011; 
Linterman et al., 2011). However, TFR cells can also promote antigen-specific high-
affinity B cell responses (Linterman et al., 2011) and influenza-specific GC reactions 
(Leon et al., 2014). Extensive crosstalk also exists between the differentiation of TFH cells 
and other effector lineages (Crotty, 2011), although the involvement of Treg cells in these 
processes remains largely unexplored. Here we show that PTEN signaling in Treg cells is 
crucial in the repression of TFH responses, and this is further linked to Treg cell stability 
and Treg cell-mediated control of TH1 responses. Strikingly, loss of PTEN in Treg cells 
results in spontaneous TFH differentiation and GC formation, and the development of 
SLE-like autoimmune symptoms. These immune defects are associated with dysregulated 
expression of many genes involved in TFH and TFR responses in Pten-deficient Treg cells. 
Furthermore, the uncontrolled TFH responses in Ptenfl/flFoxp3-Cre mice are dependent 
upon the TH1 signature cytokine IFN-?, as deletion of IFN-? considerably rectifies the 
dysregulated TFH response and autoimmune disease. Notably, the relationship between 
TH1 and TFH cells is complex and remains controversial. For instance, whereas IFN-? is 
essential in driving TFH cells in the Roquinsan/san autoimmunity model (which has a point 
mutation in the Roquin gene) (Lee et al., 2012a), it is dispensable for the differentiation 
of TFH cells induced by viral infection (Ray et al., 2014). Further, T-bet induction 
dampens rather than enhances the TFH differentiation program (Nakayamada et al., 2011). 
Our studies demonstrate that TFH and TH1 responses are coordinately regulated by Treg 
cells, with the TH1-mediated IFN-? production being a main driver of TFH and GC 
reactions. However, we cannot conclude the direct contribution of the exacerbated TH1 
response, independent of TFH cells, to the autoimmune and lymphoproliferative 
phenotypes.  
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As one of the most frequently mutated tumor suppressor genes, PTEN is 
implicated in the regulation of multiple cancer types. Selective deletion of PTEN in T 
cells results in rapid development of T cell leukemia, as well as the loss of immune 
tolerance (Suzuki et al., 2001). More recent studies unveil that these two effects can be 
dissociated, as they are derived from abnormalities in the thymus and periphery, 
respectively (Liu et al., 2010). PTEN is also implicated in the regulation of effector T cell 
responses. Deletion of Pten in activated T cells enhances effector responses but does not 
lead to autoimmunity or cancer (Soond et al., 2012). miRNAs targeting PTEN expression 
are also implicated in shaping TFH responses (Kang et al., 2013). In Treg cells, PTEN 
expression is maintained at a higher level than conventional T cells (Zeiser et al., 2008). 
PTEN restrains the abundance of Treg cells but is largely dispensable for Treg cell 
suppressive activity in vitro (Walsh et al., 2006). We found that deletion of Pten in Treg 
cells leads to the exacerbated effector T cell responses and loss of immune tolerance and 
tissue homeostasis. Pten-deficient Treg cells dominate over WT cells in mediating TFH 
and GC responses, which are mediated, at least in part, by dysregulated IFN-? expression. 
Moreover, PTEN functions in a haploinsufficient manner, in that heterozygous loss of 
Pten is sufficient to disrupt Treg cell and immune homeostasis. These results together 
establish PTEN signaling in Treg cells as a unique regulator of immune system 
homeostasis and function. 
 
How does PTEN function in Treg cells at the molecular levels? Our microarray, 
metabolic and immunological assays reveal the important role of PTEN in linking cell 
cycle and metabolic machineries and the expression of immune effector genes in Treg 
cells. Given the opposing effects of glycolytic and mitochondrial metabolism on Treg 
cells (Michalek et al., 2011a; Shi et al., 2011), the disrupted balance between these 
activities in Pten-deficient Treg cells is likely an important contributor to the phenotypic 
alteration, a notion that we are currently investigation. Of note, despite the metabolic 
functions of PTEN and PI3K signaling identified in non-immune cells, the underlying 
mechanisms are highly complex and poorly understood (Garcia-Cao et al., 2012). For 
instance, PTEN can either potentiate or inhibit mitochondrial activity (Garcia-Cao et al., 
2012; Li et al., 2013), and the metabolic functions of PTEN are associated with both 
mTORC1-dependent and independent activities (Garcia-Cao et al., 2012; Song et al., 
2011; Tandon et al., 2011). Indeed, various effector pathways downstream of PTEN have 
been identified, including PI3K-AKT, mTORC1, mTORC2, and PI3K-AKT-independent 
nuclear functions (Chi, 2012; Garcia-Cao et al., 2012; Newton and Turka, 2012; Shen et 
al., 2007; Song et al., 2011). It is therefore unexpected that our biochemical and genetic 
rescue experiments have identified mTORC2 signaling as a dominant mechanism to 
mediate PTEN functions in Treg cells. Emerging evidence highlights a crucial role of 
mTOR and metabolic signaling in Treg cells, which was believed to mainly function as a 
negative regulator of Treg cells (Delgoffe et al., 2009). However, recent genetic studies 
indicate that both loss and gain of mTORC1 activity are detrimental to Treg-mediated 
suppressive function and immune tolerance (Park et al., 2013; Wei et al., 2016; Zeng et 
al., 2013). In contrast, the physiological significance and regulatory mechanisms of 
mTORC2 are much less clear. Here our results have established the PTEN-mTORC2 axis 
as a central determinant of Treg cell stability and Treg cell-mediated control of effector T 
cell responses. Mechanistically, this signaling pathway likely orchestrates and 
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coordinates both the metabolic and transcriptional programs, such as those mediated by 
Foxo1 and Blimp1 (Ouyang et al., 2012; Shin et al., 2013), in impinging upon Treg 
stability and functions.  
 
In line with this idea, ectopic expression of Foxo1AAA, which is insensitive to 
phosphorylation downstream of AKT-mTORC2, seems to alleviate several Pten-deficient 
Treg cell phenotypes, it failed to rectify the higher frequency of Treg cells. This 
demonstrates that additional and alternative downstream targets might regulate Treg cell 
programming. We note that the loss of Treg cell stability also results from Treg cell-
specific deletion of neuropilin-1 and Foxo1 (Delgoffe et al., 2013; Ouyang et al., 2012), 
although the cellular phenotypes and effects on immune homeostasis are rather distinct 
from the Ptenfl/flFoxp3-Cre model. Since the effects on TFH and humoral responses in the 
other genetic models have not been described, further work is required to explore the 
crosstalk between these molecular pathways in Treg cells. 
 
Briefly, studying the downstream signaling pathway Foxo1 further to expand its 
role during the loss of PTEN in Treg cells would provide valuable insights regarding 
production of autoantibodies, programming of TFH and TFR cells and Treg metabolism. 
Additional studies would include dissecting mechanistic role of PTEN in controlling TH1 
responses and TFR cells, if and how mTOR or PI3K inhibitors would restore function and 
stability in PTEN-deficient Treg cells. Furthermore, examination of additional pathways 
such as SGK1, an enzyme downstream of mTORC2 that promotes Foxo1 
phosphorylation, would be insightful. 
 
In summary, our study has unveiled the interplay between the PTEN-mTORC2 
signaling axis and the transcriptional and metabolic regulation in Treg cells as a new 
mechanism for maintaining Treg cell stability and regulating Treg cell-mediated 
repression of TH1 and TFH responses. Given the potent effects of selective Pten deficiency 
in Treg cells on immune tolerance and tissue homeostasis, the identification of this 
signaling axis provides a new target for therapeutic intervention of systemic autoimmune 
and lymphoproliferative diseases.  
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APPENDIX.  TSC1 PROMOTES THE DIFFERENTIATION OF MEMORY CD8+ 
T CELLS VIA ORCHESTRATING THE TRANSCRIPTIONAL AND 
METABOLIC PROGRAMS* 
 
 
Introduction 
 
Memory CD8+ T cells play an important role in protective immunity and have the 
capability to mount robust recall responses upon reexposure to tumor or pathogen-
derived antigens. Recent studies have revealed developmental pathways and 
transcriptional programs important for the generation of long-lived memory cells (Kaech 
and Cui, 2012). Antigen-activated CD8+ T cells rapidly expand and generate 
heterogeneous populations of effector cells, namely short-lived effector cells (SLECs) 
and memory-precursor effector cells (MPECs) (Joshi et al., 2007; Sarkar et al., 2008). 
SLECs (CD127loKLRG1hi) exhibit strong cytotoxicity with high expression of perforin 
and granzymes and are predisposed to cell death, whereas MPECs (CD127hiKLRG1lo) 
display the increased potential to survive and further differentiate into mature memory 
CD8+ T cells. The fate decision between SLECs and MPECs is important for effector 
functions and memory differentiation and is shaped by a number of transcription factors. 
For instance, transcription factors Eomes and Bcl6 promote the generation of MPECs, 
whereas Blimp1 and T-bet drive the transcriptional programs for SLEC differentiation 
(Kaech and Cui, 2012). 
 
T cells dynamically reprogram cellular metabolism to fulfill the bioenergetics and 
biosynthetic requirements for their survival, proliferation, and differentiation (MacIver et 
al., 2013a; Pearce et al., 2013; Wang and Green, 2012). Naïve and memory T cells use 
catabolic metabolism via oxidative phosphorylation, especially fatty acid oxidation, to 
produce ATP for their survival. In contrast, antigen-stimulated T cells switch to 
anabolism to support their rapid proliferation through up-regulating expression of genes 
involved in multiple metabolic pathways, including glycolysis, fatty acid and cholesterol 
biosynthesis, and amino acid transport (Kidani et al., 2013; Sinclair et al., 2013; Wang et 
al., 2011; Yang et al., 2013). Emerging studies indicate that distinct metabolic pathways 
contribute to the fate decisions of effector and memory T cells. For instance, the 
increased glycolytic metabolism promotes effector T-cell generation (Sukumar et al., 
2013), whereas oxidative phosphorylation and mitochondrial spare respiratory capacity 
facilitate memory T-cell differentiation (Pearce et al., 2009; van der Windt et al., 2012). 
Recent studies have also identified transcriptional regulators of cell metabolism that 
promote effector T-cell differentiation, including HIF1 and IRF4 (Doedens et al., 2013; 
Finlay et al., 2012; Man et al., 2013; Yao et al., 2013). In contrast, how cell metabolism 
 
 
------------------------ 
*Appendix reprinted with permission Shrestha, S., et al. (2014). "Tsc1 promotes the 
differentiation of memory CD8+ T cells via orchestrating the transcriptional and 
metabolic programs." Proceedings of the National Academy of Sciences of the United 
States of America 111(41): 14858-14863. 
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is regulated by immune signaling pathways in effector and memory T-cell differentiation 
remains unclear. 
 
mTOR signaling has been implicated in the control of effector and memory T-cell 
differentiation (Araki et al., 2009; Li et al., 2011; Rao et al., 2010). Inhibition of mTOR 
signaling by rapamycin promotes the generation of MPECs and their subsequent 
differentiation into memory T cells upon acute lymphocytic choriomeningitis virus 
(LCMV) infection (Araki et al., 2009). In vitro treatment of effector cells with rapamycin 
also enhances the developmental potential of memory cells through increasing the 
expression of Eomes at the expense of T-bet (Rao et al., 2010). Moreover, rapamycin 
enhances the ability of homeostatic proliferation-induced memory CD8+ T cells against 
tumor challenge via regulating the expression of Eomes and T-bet (Li et al., 2011). 
Despite these studies linking mTOR signaling to the regulation of memory T-cell 
differentiation, the upstream regulators of mTOR remain unresolved. Notably, deletion of 
Pten does not cause significant defects in memory formation in LCMV infection (Hand et 
al., 2010). Moreover, whether mTOR or the canonical activator AKT impacts memory T-
cell differentiation via metabolic pathways or other pathways such as cell migration is 
unclear (Finlay and Cantrell, 2011). Of note, AKT regulates the differentiation and 
function of effector CD8+ T cells via orchestrating the transcriptional program instead of 
cellular metabolism (Macintyre et al., 2011). Therefore, the upstream and downstream 
mechanisms for mTOR-dependent regulation of memory generation remain to be 
defined. 
 
Tuberous sclerosis 1 (TSC1), a negative regulator of mTORC1 signaling 
(Laplante and Sabatini, 2012), has been implicated in T-cell homeostasis and anergy 
(O'Brien et al., 2011; Wu et al., 2011; Xie et al., 2012; Yang et al., 2011). We and others 
have demonstrated that deletion of Tsc1 in naïve T cells disrupts their quiescence and 
survival and dampens T-cell–mediated primary responses to bacterial infection (O'Brien 
et al., 2011; Wu et al., 2011; Yang et al., 2011). Additionally, Pollizzi et al. has recently 
shown the importance of Tsc2, the gene encoding TSC2 that forms heterodimer with 
TSC1, in CD8+ T cell programming. Specific deletion of Tsc2 in CD8+ T cells by using 
Cd4-Cre mice resulted in terminal differentiation of effector cells, which demonstrated 
increased glycolytic activity and were unable to undergo further programming into the 
memory phase (Pollizzi et al., 2015). To circumvent the crucial requirement of TSC1 in 
naïve T-cell homeostasis, we developed a mouse model to specifically delete Tsc1 in 
antigen-experienced CD8+ T cells. We describe here that TSC1 plays a critical role in 
promoting the differentiation and function of memory CD8+ T cells in Listeria 
monocytogenes (LM) infection. In contrast to the deletion of Tsc1 in naïve T cells, mice 
with Tsc1 deficiency in antigen-experienced CD8+ T cells retained normal effector 
responses but were markedly impaired in the recall response to antigen reexposure. 
Mechanistically, Tsc1 deficiency diminished the generation of MPECs while promoting 
the development of SLECs in a cell-intrinsic manner. The functional genomic analysis 
indicated that TSC1 coordinated gene expression programs underlying immune function, 
transcriptional regulation, and cell metabolism. Furthermore, Tsc1 deletion led to 
excessive mTORC1 activity and dysregulated metabolism, including glycolysis and 
oxidative phosphorylation, in response to IL-15 stimulation. These findings establish a 
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previously unappreciated role of TSC1 in linking immune signaling and cell metabolism 
to orchestrate memory CD8+ T-cell development and function. 
 
 
Results 
 
 
Tsc1-deficient T cells mount normal effector responses but are impaired to 
transition into memory cells 
 
TSC1 is essential to maintain the quiescence of naïve T cells. T-cell–specific 
deletion of Tsc1 in mice via Cd4–Cre impairs naïve T-cell survival, homeostasis, and 
primary immune responses (O'Brien et al., 2011; Wu et al., 2011; Yang et al., 2011). 
Hence, this mouse model impedes the investigation of TSC1 functions in antigen-specific 
effector and memory responses. To this end, we crossed mice carrying the floxed Tsc1 
alleles (Tsc1fl/fl) with those expressing the Cre recombinase under control of the 
Granzyme B promoter (GzmB–Cre) (Jacob and Baltimore, 1999) to specifically delete 
Tsc1 in antigen-experienced CD8+ T cells (called “Tsc1−/− mice” here). Under steady 
state, Tsc1−/− mice had normal distribution of CD4+ and CD8+ T cells (Figure A-1A). 
Homeostasis of these T cells was also undisrupted, as indicated by the normal expression 
of CD62L, CD44, and CD127 (Figure A-1B and C), consistent with the absence of Tsc1 
deletion in naïve CD8+ T cells (Figure A-1D). 
 
To examine whether Tsc1 deficiency affects effector responses, we challenged 
wild-type GzmB-Cre-negative Tsc1fl/fl mice (called “WT mice” here) and Tsc1−/− mice 
with L. monocytogenes expressing the chicken ovalbumin (LM–OVA), and assessed 
antigen-specific CD8+ T cells in various organs at day 9 postinfection (p.i.), the peak 
phase of effector cell expansion. Real-time PCR results showed that Tsc1 genomic DNA 
and mRNA were both effectively deleted (Figure A-2A and B). However, the frequency 
and number of OVA-specific CD8+ T cells were similar between WT and Tsc1−/− mice in 
the various organs examined (Figure A-2C). Also, Tsc1−/− effector cells in the spleen and 
liver showed slightly increased proliferation and largely normal death, as indicated by 
BrdU incorporation and active caspase-3 staining, respectively (Figure A-2D and E). To 
measure the ability of antigen-specific CD8+ T cells to produce cytokines, we 
restimulated splenocytes from infected mice with the OVA257–264 [comprised of amino 
acids Ser-Ile-Ile-Asn-Phe-Glu-Lys-Leu (SIINFEKL)] peptide ex vivo. WT and Tsc1−/− 
splenocytes had similar frequency and number of antigen-specific T cells producing IFN-
γ and TNF-α (Figure A-2F). Thus, loss of TSC1 in antigen-experienced CD8+ T cells 
does not significantly affect effector responses. 
 
After the rapid expansion of antigen-experienced CD8+ T cells, the majority of 
effector cells undergo cell death, whereas only a small subset survives and differentiates 
into memory cells (Kaech and Cui, 2012). We investigated whether Tsc1 deficiency 
impairs the transition from effector to memory T cells by following the dynamics of 
OVA-specific T cells in the blood of WT and Tsc1−/− mice infected with LM–OVA. After 
clonal expansion, OVA-specific T cells in WT mice underwent the contraction phase,  
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Figure A-1. Normal homeostasis of CD4+ and CD8+ T cells in Tsc1−/− mice under 
steady state. 
(A) Flow cytometry of conventional T cells in the spleen, peripheral lymph nodes 
(PLNs), liver, and bone marrow (BM) from WT and Tsc1−/− mice. (B) Expression of 
CD62L and CD44 (Left) and the frequency (Center) and number (Right) of naïve CD4+ 
and CD8+ (CD62LhiCD44lo) T cells. (C) Expression of CD127 on CD8+ T cells from WT 
and Tsc1−/− mice. (D) Real-time PCR analysis of Tsc1 mRNA expression in naïve CD8+ 
(CD62LhiCD44lo) T cells from WT and Tsc1−/− mice. Data are representative of two 
independent experiments and are presented as the mean ± SEM. 
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Figure A-2. TSC1 deficiency does not impact the effector response of CD8+ T cells. 
WT and Tsc1−/− mice were infected with LM–OVA and analyzed at day 9 p.i. (A and B) 
Real-time PCR analysis of Tsc1 gDNA (A) and mRNA expression (B) in Kb -OVA+ 
CD8+ T cells at day 9 p.i. (C) Representative flow cytometry plots of CD8+ T cells (Left) 
and the frequency (Center) and number (Right) of Kb-OVA+ CD8+ T cells. (D) BrdU 
staining of Kb-OVA+ CD8+ T cells in the spleen and liver of WT and Tsc1−/− mice at day 
9 p.i. (Left) and the frequency of BrdU+ cells (Right). (E) Active caspase-3 staining of Kb 
-OVA+ CD8+ T cells in the spleen and liver of WT and Tsc1−/− mice at day 9 p.i. (Left) 
and the frequency of active caspase-3+ cells (Right). (F) At day 9 p.i., splenocytes from 
WT and Tsc1−/− mice were restimulated with the SIINFEKL peptide for intracellular 
cytokine staining of IFN-γ and TNF-α. Shown are representative flow cytometry plots of 
CD8+ T cells (Left) and the frequency (Center) and number (Right) of IFN-γ+ and TNF-
α+ CD8+ T cells. Data are representative of two independent experiments (B–F) or one 
experiment (A; n = 3 mice per group) and are presented as the mean ± SEM. 
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followed by the formation of long-lived memory cells (Figure A-3A). Consistent with 
the data described above, the frequency of Tsc1−/− OVA-specific T cells was largely 
normal at day 9, but the decline was much greater than that of WT cells (Figure A-3A). 
Therefore, loss of TSC1 resulted in a progressive defect in the generation of memory T 
cells. To further address this question, we measured OVA-specific T cells in the spleen of 
WT and Tsc1−/− mice at different time points. At day 18 p.i., when Tsc1−/− splenocytes 
had yet to show significant reduction of antigen-specific CD8+ T cells (Figure A-3B), 
these cells already up-regulated caspase-3 activity (Figure A-4A). In contrast, Tsc1−/− 
cells showed largely normal proliferation at this stage, as indicated by Ki-67 expression 
and BrdU incorporation (Figure A-4B). Moreover, at day 41 p.i., the number of OVA-
specific CD8+ T cells was significantly reduced in the spleen and liver of Tsc1−/− mice 
(Figure A-3B and C). We next examined cytokine production by memory CD8+ T cells 
at day 41 via restimulating splenocytes with the OVA peptide ex vivo. Consistent with the 
reduced number of memory CD8+ T cells, Tsc1−/− mice had fewer antigen-specific cells 
producing IFN-γ and TNF-α than WT mice (Figure A-3D). Therefore, TSC1 depletion in 
antigen-experienced CD8+ T cells impairs the transition from effector responses to 
memory formation. 
 
 
TSC1 deletion impairs the recall response of memory cells  
 
One hallmark of memory T cells is their ability to mount accelerated recall 
responses to antigen reexposure. To examine the role of TSC1 in this process, we used 
LM–OVA to rechallenge WT and Tsc1−/− mice at day 35 after primary infection. At day 4 
after the secondary infection, WT mice mounted robust recall responses in the blood, 
spleen, and liver (Figure A-5A). In contrast, the frequency and number of OVA-specific 
CD8+ T cells were significantly reduced in Tsc1−/− mice (Figure A-5A). We next 
assessed cytokine production of WT and Tsc1−/− splenocytes after restimulation with the 
OVA peptide ex vivo. Tsc1−/− mice had reduced frequency and number of T cells 
producing IFN-γ and TNF-α compared with WT mice (Figure A-5B). Therefore, Tsc1 
deficiency impairs the recall response of memory cells. 
 
One potential caveat of the experimental system above was that the defective 
recall response of Tsc1−/− memory T cells could be ascribed to the uneven numbers of 
memory T cells in WT and Tsc1−/− mice before rechallenge. To circumvent this 
possibility, we sorted OVA-specific memory T cells from WT and Tsc1−/− mice 
(CD45.2+) at day 41 p.i. and adoptively transferred equal numbers of WT and Tsc1−/− 
memory T cells into naïve recipients (CD45.1+), followed by LM–OVA infection 24 h 
later. At day 5 p.i., we assessed the frequency of donor-derived cells in various organs. 
The frequency of Tsc1−/− donor cells was significantly reduced compared with that of WT 
donor cells in all organs examined (Figure A-5C). We conclude that TSC1 is required 
for the recall response of memory cells upon antigen reexposure. 
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Figure A-3. The absence of TSC1 diminishes the generation of memory T cells. 
(A) The frequency of Kb-OVA+ CD8+ T cells in the blood from WT and Tsc1−/− mice 
infected with LM–OVA at the indicated time points was determined by flow cytometry 
(*P < 0.05, **P < 0.01). (B) Number of Kb-OVA+ CD8+ T cells in the spleen from WT 
and Tsc1−/− mice at days 0, 9, 18, and 41 p.i. (C) Flow cytometry of CD8+ T cells (Left) 
and the number of Kb-OVA+ CD8+ T cells (Right) in the spleen and liver from WT and 
Tsc1−/− mice at day 41 p.i. (D) Splenocytes from WT and Tsc1−/− mice at day 41 p.i. were 
restimulated with the SIINFEKL peptide for intracellular cytokine staining of IFN-γ and 
TNF-α. Shown are representative flow cytometry plots of CD8+ T cells (Left) and the 
number (Right) of IFN-γ+ and TNF-α+ CD8+ T cells. Data are representative of three 
independent experiments and are presented as the mean ± SEM. 
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Figure A-4. Proliferation and survival of Tsc1-deficient CD8+ T cells during the 
contraction phase. 
Flow cytometry of active caspase-3+ (A), Ki -67+ and BrdU+ (B) in Kb-OVA+ CD8+ T 
cells in the spleen from WT and Tsc1−/− mice at day 18 p.i. Data are representative of two 
independent experiments and are presented as the mean ± SEM. 
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Figure A-5. TSC1 deficiency impairs the recall response of memory CD8+ T cells. 
(A) WT and Tsc1−/− mice were infected with LM–OVA and rechallenged with LM–OVA 
35 d later. The recall response of memory CD8+ T cells was examined at day 4 after 
secondary infection. Shown are representative flow cytometry plots of CD8+ T cells 
(Left) and the frequency (Center) and number (Right) of Kb-OVA+ CD8+ T cells. (B) At 
day 4 after the secondary infection, splenocytes from WT and Tsc1−/− mice were isolated 
and restimulated with the SIINFEKL peptide for intracellular cytokine staining of IFN-γ 
and TNF-α. Shown are representative flow cytometry plots of CD8+ T cells (Left) and the 
frequency (Center) and number (Right) of IFN-γ+ and TNF-α+ CD8+ T cells. (C) Memory 
CD8+ T cells (CD45.2+) sorted from WT and Tsc1−/− mice at day 41 p.i. were transferred 
into naïve CD45.1+ recipients. At 24 h, the recipients were challenged with LM–OVA 
and analyzed 5 d later for CD45.1 and CD45.2 staining of CD8+ T cells (Left) and the 
frequency of CD45.2+ donor cells (Right). BM, bone marrow; PLN, peripheral lymph 
nodes. Data are representative of two independent experiments and are presented as the 
mean ± SEM. 
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A cell-intrinsic requirement of TSC1 in memory formation and function 
 
Given the role of TSC1 in the homeostasis of naïve T cells (O'Brien et al., 2011; 
Wu et al., 2011; Yang et al., 2011), it remains possible that the T-cell receptor (TCR) 
repertoire of Tsc1−/− T cells could be altered and contributed to the defects observed 
above. We therefore crossed Tsc1−/− mice onto the TCR-transgenic background (OT-I) in 
which CD8+ T cells expressed a SIINFEKL peptide-specific TCR. We mixed 
congenically marked naive OT-I and Tsc1−/−OT-I cells at a 1:1 ratio and cotransferred 
them to WT recipient mice, followed by LM–OVA infection. This adoptive transfer 
system also allowed us to exclude the effects of potential Tsc1 deletion in cells other than 
CD8+ T cells. Consistent with the normal effector responses observed in Tsc1−/− mice 
(Figure A-2), the frequencies of OT-I and Tsc1−/−OT-I cells were comparable at day 9 
p.i. (Figure A-6A). However, at day 29 and 57 p.i., the percentage of Tsc1−/−OT-I cells 
was substantially lower than that of OT-I cells (Figure A-6A), indicative of a defect in 
the generation of memory cells. Upon LM–OVA rechallenge, the frequencies of 
Tsc1−/−OT-I cells were also significantly lower than those of OT-I cells in various organs 
examined (Figure A-6B). Moreover, among IFN-γ– or TNF-α–producing cells in the 
recipient mice, the majority of them were derived from OT-I instead of Tsc1−/−OT-I 
donor cells (Figure A-6C and D). These results establish a cell-intrinsic role of TSC1 in 
promoting the formation and function of memory CD8+ T cells. 
 
 
Impaired differentiation of memory precursors in the absence of TSC1 
 
Aside from rapid expansion, effector cells differentiate into diverse subsets with 
distinct potentials for the formation of memory T cells: MPECs (CD127hiKLRG1lo) and 
SLECs (CD127loKLGR1hi) (Joshi et al., 2007; Sarkar et al., 2008). To investigate 
whether TSC1 deficiency affects the differentiation of MPECs and SLECs, we examined 
the expression of CD127 and KLRG1 on WT and Tsc1−/− effector cells at day 9 p.i. We 
found that Tsc1−/− OVA-specific CD8+ T cells had markedly reduced frequency and 
number of MPECs, whereas the frequency and number of SLECs were increased  
(Figure A-7A). Similar findings were observed in Tsc1−/−OT-I T cells in the adoptive 
transfer system (Figure A-8A). Moreover, to exclude the potential role of TSC1 in cell 
survival (Figure A-4A), we crossed Tsc1−/− mice with mice expressing a Bcl2 transgene 
in lymphocytes (labeled as Bcl2-Tg) (Yang et al., 2011). Following LM–OVA infection, 
Tsc1−/− Bcl2-Tg T cells showed reduced MPECs but increased SLECs, compared with the 
Bcl2-Tg counterparts (Figure A-8B). Taken together, these results reveal an intrinsic 
effect of Tsc1 deficiency on the fate decisions between MPECs and SLECs. 
 
The differentiation of activated CD8+ T cells into MPECs and SLECs is 
controlled by the differential expression of specific transcription factors, with Eomes and 
Bcl6 important in promoting the differentiation of MPECs (Kaech and Cui, 2012). The 
expression of these transcription factors in antigen-specific CD8+ T cells from WT and 
Tsc1−/− mice at day 9 p.i. was largely comparable (Figure A-9). However, TSC1 
deficiency considerably enhanced the expression of Blimp1 and T-bet, which are crucial 
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Figure A-6. TSC1 promotes memory CD8+ T-cell generation through cell-intrinsic 
mechanisms. 
Naïve CD8+ T cells from OT-I+ (CD45.2+) and Tsc1−/−OT-I+ (CD45.1.2+) mice were 
isolated, mixed at a 1:1 ratio, and transferred to CD45.1+ recipients, followed by LM–
OVA infection 1 d later. (A) The frequencies of OT-I+ (CD45.2+) and Tsc1−/−OT-I+ 
(CD45.1.2+) donor T cells out of the total Kb-OVA+ CD8+ cells in the blood at days 9, 29, 
and 57 p.i were analysed by flow cytometry. (B–D) At day 57 p.i., mice were 
rechallenged with LM–OVA and analyzed 3 d later by flow cytometry. (Right) The 
frequencies and numbers of OT-I+ (CD45.2+) and Tsc1−/−OT-I+ (CD45.1.2+) out of the 
total Kb-OVA+ CD8+ T cells from the blood, spleen, and liver (B) or out of splenic IFN-
γ+ (C) or TNF-α+ (D) CD8+ T cells after restimulation with SIINFEKL peptide. Data are 
representative of three independent experiments and are presented as the mean ± SEM. 
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Figure A-7. TSC1 is required for the differentiation of MPECs. 
(A) Flow cytometry of CD127 and KLRG1 (Top) on Kb-OVA+ CD8+ T cells from WT 
and Tsc1−/− mice at day 9 p.i., and the frequency (Middle) and number (Bottom) of 
MPECs (CD127hiKLRG1lo) and SLECs (CD127loKLRG1hi). (B) Intracellular staining of 
Blimp1 and T-bet in splenic Kb-OVA+ CD8+ T cells from WT and Tsc1−/− mice at day 9 
p.i. (C) Intracellular staining of Blimp1 and T-bet in MPECs, SLECs, and 
CD127hiKLRG1hi cells in splenic Kb-OVA+ CD8+ T cells from WT and Tsc1−/− mice at 
day 9 p.i. (D) Flow cytometry of GzmB, CD244, Tim-3, and CTLA-4 at day 9 p.i. in Kb-
OVA+ CD8+ T cells from WT and Tsc1−/− mice. Mean fluorescent intensity (MFI) is 
presented above the plots (WT, red; Tsc1−/−, blue; B–D). Data are representative of three 
independent experiments and are presented as the mean ± SEM. 
 
 131 
 
 
Figure A-8. Intrinsic role of TSC1 in the differentiation of memory precursors. 
(A) Naïve CD8+ T cells from OT-I+ (CD45.2+) and Tsc1−/−OT-I+ (CD45.1.2+) mice were 
isolated, mixed at a 1:1 ratio, and transferred to CD45.1+ recipients, followed by LM–
OVA infection 1 d later. Flow cytometry of CD127 and KLRG1 expression and 
frequencies of memory-precursor effector cells (MPECs) and short-lived effector cells 
(SLECs) from OT-I+ (CD45.2+) and Tsc1−/−OT-I+ (CD45.1.2+) donor T cells out of the 
total Kb-OVA+ CD8+ T cells at day 7 p.i. (B) Flow cytometry of CD127 and KLRG1 and 
frequencies of MPECs and SLECs in Kb-OVA+ CD8+ T cells from Bcl2-transgenic (Tg) 
and Tsc1−/− Bcl2-Tg mice at day 8 p.i. Data are representative of two independent 
experiments and are presented as the mean ± SEM. 
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Figure A-9. Expression of transcription factors implicated in memory T-cell 
differentiation. 
Intracellular staining of Eomes and Bcl6 in splenic Kb-OVA+ CD8+ T cells from WT and 
Tsc1−/− mice at day 9 p.i. Data are representative of three independent experiments. 
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factors for the development of SLECs and cytotoxic T-lymphocyte functions (Kaech and 
Cui, 2012)  (Figure A-7B). The altered expression of Blimp1 and T-bet was observed in 
subdivided populations including MPECs, SLECs, and CD127+KLRG1+ cells  
(Figure A-7C), highlighting a direct effect of TSC1 deficiency on these transcription 
factors. Moreover, Tsc1−/− CD8+ T cells had elevated expression of Granzyme B and 
immune inhibitory receptors CD244 (2B4), Tim-3, and CTLA-4 (Blackburn et al., 2009; 
Jin et al., 2010; Wherry, 2011) (Figure A-7D). Therefore, consistent with the impaired 
memory development and MPEC formation, TSC1 deficiency enhances the expression of 
effector-promoting transcription factors Blimp1 and T-bet and multiple immune 
inhibitory receptors. 
 
 
Tsc1-dependent gene expression programs in antigen-specific CD8+ T cells 
 
We performed functional genomics to identify additional pathways controlled by 
TSC1 by comparing global gene expression profiles of WT and Tsc1−/− OVA-specific 
CD8+ T cells sorted from mice at day 9 p.i. Tsc1−/− cells contained a total of 420 
increased probes and 378 decreased probes by greater than 0.5 log2 fold change between 
the comparison (Figure A-10A). The heat maps in Figure A-10B showed that Tsc1−/− 
CD8+ T cells differentially expressed multiple genes (with log2 fold change > 0.5) 
associated with the differentiation of effector and memory CD8+ T cells, including 
receptors and secreted factors (Il12rb2, Gzmb, Sell, and IL7r) and transcription factors 
(Tcf7, Bach2, and Klf4). Additionally, Tsc1−/− CD8+ T cells had altered expression of 
genes involved in various metabolic pathways, including glycolysis (Tpi1), cholesterol 
synthesis (Fdps, Hmgcs1, and Insig1), and fatty acid synthesis (Fads1 and Elovl7) 
(Figure A-10B). Therefore, TSC1 coordinates the expression of immune response and 
metabolic genes in antigen-specific CD8+ T cells. 
 
Given the effects of TSC1 on the differentiation of MPECs and SLECs, it remains 
possible that the altered gene profiles of Tsc1−/− cells were simply secondary to the 
disrupted ratios of MPECs and SLECs. To address this issue, we compared TSC1-
dependent targets with the genes differentially expressed in KLRG1hi and KLRG1lo CD8+ 
T cells in the public database (Hess Michelini et al., 2013). Out of 798 probes with a log2 
fold change > 0.5 in Tsc1−/− cells, 621 were matched to this database and were included 
for further analysis (Supplementary Data 2 – Tsc1 Datasheet). These TSC1-dependent 
targets were partitioned into four distinct clusters that differed in their relationship to the 
specific gene targets in KLRG1hi cells (Figure A-10C). A salient feature was that the 
majority of TSC1-dependent targets (408 out of 621 probes) fell into cluster 1 (red 
circles), in which their expression was comparable between KLRG1hi and KLRG1lo cells 
(<0.5 log2 fold change). Further, cluster 2 (blue circles) contained 38 probes that showed 
the opposite direction of change in expression, and cluster 3 (green circles) contained 49 
probes that were differentially expressed in both types of comparisons, but to a greater 
extent in KLRG1hi cells compared with Tsc1−/− cells. Only cluster 4 (yellow circles, 126 
probes) contained the target genes with equal magnitude of change (>0.5 log2 fold 
change) in both Tsc1−/− and KLRG1hi cells, thus representing concordant changes in both 
types of cells. Overall, ~80% of all TSC1-dependent gene targets are independent of  
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Figure A-10. TSC1-dependent gene expression profiles in antigen-experienced 
CD8+ T cells.  
(A) Scatterplot comparison of global gene expression profiles between WT and Tsc1−/− 
Kb-OVA+ CD8+ T cells sorted from mice at day 9 p.i.; transcripts with >0.5 log2 fold 
change are highlighted (WT, n = 4; Tsc1−/−, n = 5). (B) Heat maps of differentially 
expressed genes in Kb-OVA+ CD8+ T cells (with >0.5 log2 fold change), with genes 
upregulated or downregulated in Tsc1−/− cells shown in red and blue, respectively. (C) 
Comparison of expression changes in Tsc1−/− versus WT cells with those in KLRG1hi 
versus KLRG1lo cells. The TSC1-dependent target genes (>0.5 log2 fold change) were 
partitioned into four main clusters, shown and colored by regions (R1–R4). Numbers 
within parentheses indicate the number of probes within each subregion. (D and E) ROS 
production (D) and cell size (E) of splenic Kb-OVA+ CD8+ T cells from WT and Tsc1−/− 
mice at day 9 and 18 p.i. Data are representative of one experiment (A–C) and two 
independent experiments (D and E) and are presented as the mean ± SEM. 
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KLRG1 expression (clusters 1–3), indicating a distinct gene expression program 
controlled by TSC1. 
 
We next used the ingenuity pathway analysis (IPA) system to analyze canonical 
pathways controlled by TSC1 in activated CD8+ T cells by investigating the differentially 
expressed genes with a false discovery rate (FDR) < 0.1. Figure A-11A shows the top 11 
canonical pathways affected by Tsc1 deficiency with P < 0.01, including oxidative 
phosphorylation and mitochondria dysfunction. Finally, to identify key networks 
regulated by TSC1, we did a gene-set enrichment analysis to compare the gene 
expression profiles of WT and Tsc1−/− Kb-OVA+ CD8+ cells. This unbiased approach 
identified multiple pathways with significant enrichment, including cell cycle, cholesterol 
biosynthesis, and oxidative phosphorylation, all of which were up-regulated in Tsc1−/− 
CD8+ T cells (Figure A-11B-D). 
 
Given that oxidative phosphorylation was affected by Tsc1 deficiency in both 
GSEA and IPA analysis, we examined mitochondrial reactive oxygen species (ROS) 
production, which is associated with oxidative phosphorylation (Pearce et al., 2013). 
Tsc1−/− CD8+ T cells showed increased ROS production at day 9 and 18 p.i.  
(Figure A-10D). Moreover, Tsc1−/− CD8+ cells had larger cell sizes than WT cells 
(Figure A-10E), indicative of increased cell growth. Altogether, these data indicate that 
TSC1 coordinates diverse pathways involved in immune function, transcriptional 
regulation, and cell growth and metabolism. 
 
 
Dysregulated mTORC1 and metabolic activities in Tsc1-deficient CD8+ T cells 
 
The cytokines IL-2 and IL-15 are critical for the development and maintenance of 
CD8+ effector and memory T cells, respectively (Mitchell et al., 2010). To understand 
upstream and downstream mechanisms underlying TSC1-dependent memory T-cell 
differentiation, we used an in vitro culture system that mimics the programs of effector 
and memory T-cell differentiation (van der Windt et al., 2012; Weninger et al., 2001) and 
examined the effect of acute deletion of Tsc1 in this system. To this end, we crossed 
Tsc1fl/fl with Rosa26–Cre–ERT2 (CreER) and OT-I transgenic mice. We sorted naïve 
CD8+ T cells from Tsc1+/+ CreER+ OT-I and Tsc1fl/fl CreER+ OT-I mice and activated 
them with OVA and IL-2 in the presence of 4-hydroxytamoxifen (4-OHT) for 4 d, 
followed by an additional culture in either IL-2 or IL-15. The deletion of Tsc1 after 4-
OHT treatment was confirmed by real-time PCR analysis (Figure A-12A), which was 
also reflected in the increased cell size (Figure A-12B). IL-2 and IL-15 induce distinct 
effects on T-cell growth and metabolic activities (Cornish et al., 2006; van der Windt et 
al., 2012), although how these metabolic programs are regulated is poorly defined. We 
therefore examined oxygen consumption rate (OCR) and extracellular acidification rate 
(ECAR), which denote mitochondria respiration and glycolysis, respectively, in cells 
cultured with IL-2 or IL-15. Consistent with previous observations (van der Windt et al., 
2012), IL-15 mediated a stronger effect on OCR than IL-2 did, whereas IL-2 but not IL-
15 potently elevated ECAR activity (Figure A-13A and B). Importantly, Tsc1 deficiency 
markedly enhanced ECAR and OCR in cells cultured with IL-15, but effects were very  
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Figure A-11. Dysregulated cell metabolism in Tsc1-deficient T cells. 
(A) Ingenuity pathway analysis of canonical pathways controlled by Tsc1 in Kb-OVA+ 
CD8+ T cells sorted from mice at day 9 p.i. (FDR < 0.1). (B–D) Gene set enrichment 
analysis  reveals the overrepresentation of signature genes in cell-cycle mitotic (B), 
cholesterol biosynthesis (C), and oxidative phosphorylation (D) in TSC1-deficient CD8+ 
T cells at day 9 p.i. (n = 4–5 mice per genotype). The middle part of the plots shows the 
distribution of the genes in each gene set (“Hits”) against the ranked list of genes. The 
lists on the left show the top genes in the leading edge subset. NES, normalized 
enrichment score. 
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Figure A-12. TSC1-dependent effects on cell size and glycolytic activity in activated 
Tsc1fl/fl CreER+ OT-I+ cells upon 4-OHT treatment. 
Naïve CD8+ T cells from Tsc1+/+ CreER+ OT-I+ (WT) and Tsc1fl/fl CreER+ OT-I+ 
(Tsc1CreER) mice were stimulated with OVA in the presence of IL-2 and 4-OHT for 4 d, 
followed by analysis of Tsc1 mRNA expression (A), cell size (B), and glycolytic activity 
after IL-15 stimulation for 24 h in the absence or presence of rapamycin (Rapa) (C). Data 
are representative of two independent experiments. 
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Figure A-13. TSC1 deficiency leads to dysregulated mTORC1 activity and 
metabolism in activated CD8+ T cells.  
(A and B) Naïve CD8+ T cells from OT-I+Tsc1+/+ CreER+ (WT) and OT-I+Tsc1fl/fl 
CreER+ (Tsc1CreER) mice were stimulated with OVA in the presence of IL-2 and 4-OHT 
for 4 d, and live cells were isolated and cultured with IL-15 or IL-2 for 5 d. OCR and 
ECAR were measured in IL-15 (A) and IL-2–cultured cells (B). (C) Phosphorylation of 
S6 in WT and Tsc1CreER cells activated with OVA and then stimulated with IL-2 or IL-15 
for 18 h. Numbers below lanes indicate band intensity relative to that of β-actin (loading 
control). (D) Flow cytometry of S6 phosphorylation in WT and Tsc1CreER cells activated 
with OVA and then stimulated with IL-15 for 1 and 2 d in the absence or presence of 
rapamycin (Rapa). (E and F) OCR (E) and ECAR (F) of WT and Tsc1CreER cells 
activated with OVA and then stimulated with IL-15 for 24 h in the absence or presence of 
rapamycin. (G and H) Flow cytometry of CD62L, Bcl2 (G), and caspase-3 activity (H) in 
WT and Tsc1CreER cells activated with OVA and then stimulated with IL-15 for 2–3 d in 
the absence or presence of rapamycin. Data are representative of three independent 
experiments and are presented as the mean ± SEM. 
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modest in cells cultured with IL-2 (Figure A-13A and B). Thus, Tsc1 deletion results in 
dysregulated metabolic activity during IL-15–mediated differentiation of memory T cells. 
 
Moreover, compared with Tsc1-sufficient controls, Tsc1-deficient T cells up-
regulated mTORC1 activity, as indicated by the increased phosphorylation of the 
ribosomal protein S6. Notably, the extent of up-regulation over control cells was much 
more profound in IL-15–stimulated conditions (~7.5-fold) compared with IL-2–
stimulated conditions (~2.5-fold) (Figure A-13C). Furthermore, treatment of IL-15–
stimulated cells with rapamycin considerably blocked the dysregulated mTORC1  
(Figure A-13D), OCR (Figure A-13E), and ECAR activities (Figure A-13F), as well as 
T-cell glycolytic activity (Figure A-12C). Therefore, excessive mTORC1 activation in 
the absence of TSC1 drives the metabolic dysregulation. Moreover, compared with IL-2, 
IL-15 has more of a stringent requirement for TSC1 functions in actively suppressing 
mTORC1 and mTORC1-dependent metabolic activities. 
 
Associated with dysregulated metabolism, Tsc1-deficient cells down-regulated 
CD62L and Bcl2 expression (Figure A-13G) but up-regulated caspase-3 activity  
(Figure A-13H). Importantly, rapamycin treatment restored the excessive activity of 
mTORC1 and the dysregulated expression of CD62L, Bcl2, and caspase-3 activity 
(Figure A-13G and H). Therefore, TSC1 links mTORC1 activation, cell metabolism, and 
immune regulation. 
 
 
Discussion 
 
In this study, we reveal an important function of TSC1 in promoting the 
differentiation and function of memory CD8+ T cells in bacterial infection. By 
developing a mouse model to ablate Tsc1 specifically in antigen-experienced CD8+ T 
cells, we found that TSC1 is dispensable for effector responses at the expansion phase, 
but is essential for the formation of memory CD8+ T cells and their recall responses to 
antigen reexposure in a T-cell–intrinsic manner. Mechanistically, deficiency of TSC1 
dampens the differentiation of MPECs, associated with the impaired transcriptional and 
metabolic programs. In particular, loss of TSC1 results in excessive mTORC1 activity 
and dysregulated glycolytic and oxidative metabolism in response to IL-15 stimulation. 
These findings provide new mechanistic insight into T-cell memory formation and 
function and highlight that modulation of TSC1 function is a potential strategy to 
improve the quality and quantity of memory responses. 
 
Emerging studies highlight a pivotal role of mTOR signaling in the fate decisions 
of effector and memory T cells (Araki et al., 2009; Hand et al., 2010; Li et al., 2011; Rao 
et al., 2010), but the upstream regulators of mTOR remain unresolved. Notably, mTOR 
can be activated by AKT-independent pathways in effector CD8+ T cells (Finlay et al., 
2012; Macintyre et al., 2011), and deletion of Pten does not cause significant defects in 
memory formation (Hand et al., 2010). Here, we circumvented the requirements of 
mTOR signaling in naïve T-cell homeostasis (O'Brien et al., 2011; Wu et al., 2011; Yang 
et al., 2011) and immediate TCR activation (Yang et al., 2013), by specific ablation of 
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Tsc1 in antigen-experienced CD8+ T cells. Although Tsc1 deficiency elevates mTORC1 
activity, this does not significantly impact the generation of effector CD8+ T cells at the 
peak phase of primary responses. Instead, TSC1 function is essential to ensure proper 
differentiation between MPECs and SLECs, which is a prerequisite for the subsequent 
generation of memory T cells (Kaech and Cui, 2012). Specifically, Tsc1 deficiency 
suppresses the formation of MPECs and reciprocally promotes the formation of SLECs. 
These effects were observed in multiple independent systems including direct challenge, 
adoptive transfer of OT-I cells, and Bcl2-Tg backgrounds, thereby highlighting a direct 
role of TSC1 in cell fate decisions. Accordingly, Tsc1-deficient antigen-specific CD8+ T 
cells have increased expression of Blimp1 and T-bet, which likely suppress the function 
of transcription factors required for memory differentiation (Kaech and Cui, 2012). 
Additionally, Tsc1 deletion up-regulates inhibitory receptors associated with T-cell 
exhaustion (Blackburn et al., 2009; Jin et al., 2010; Wherry, 2011). Moreover, Tsc1 
deficiency impairs the expression of genes involved in T-cell trafficking, such as L-
selectin (encoded by Sell) and CCR7, which are required for the migration to central-
memory T cells in the T-cell areas of secondary lymphoid organs (Finlay and Cantrell, 
2011). These results indicate that TSC1 promotes memory T-cell responses, in part, by 
impinging upon the transcriptional programs required for memory precursor 
differentiation. 
 
Metabolic programs are dynamically regulated to match the differentiation and 
function of T cells (MacIver et al., 2013; Pearce et al., 2013; Wang and Green, 2012). For 
the fate decisions between effector and memory CD8+ T cells, glycolytic and lipid 
synthetic metabolism promote effector T-cell generation (Kidani et al., 2013; Sukumar et 
al., 2013), whereas oxidative phosphorylation and mitochondrial activity facilitate 
memory development (Pearce et al., 2009; van der Windt et al., 2012). From the 
microarray and bioinformatics analyses, we found that Tsc1−/− antigen-specific CD8+ T 
cells exhibit elevated expression of metabolic genes involved in glycolysis, lipid 
synthesis, and oxidative phosphorylation. Moreover, Tsc1-deficient T cells show 
enhanced glycolytic and oxidative phosphorylation rates in vitro that are closely linked 
with IL-15–mediated signaling. Although the increased glycolysis upon Tsc1 deletion is 
in agreement with impaired development of memory cells (Sukumar et al., 2013), the 
effect of the increased oxidative phosphorylation remains to be established. Notably, the 
IPA analysis indicates that Tsc1 deficiency impinges upon both oxidative 
phosphorylation and mitochondria function. Further, loss of TSC1 results in excessive 
production of mitochondrial ROS. These findings indicate that TSC1 functions to ensure 
proper regulation of the metabolic programs, the disruption of which may contribute to 
impaired memory T-cell differentiation. 
 
A recent study investigated the role of TSC2 in CD8+ T cell function. T cell-
specific deletion of Tsc2 (referred to as Tsc2-/-) increased glycolytic activity in CD8+ T 
cells, and Tsc2-deficient CD8+ T cells were unable to differentiate into memory CD8+ T 
cells (Pollizzi et al., 2015). However, differences in terms of effector function exist in 
between Tsc1−/− and Tsc2−/− mice. The potential mechanism for this difference might due 
to cell death processes, as Bcl2 expression and activation-induced cell death are not 
affected in Tsc2−/− mice, unlike Tsc1−/− mice. Additionally, presence mTORC2 activity in 
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Tsc2−/− mice resulted in potent effector CD8+ T cell function that was reduced in Tsc1−/− 
mice (O'Brien et al., 2011; Pollizzi et al., 2015; Wu et al., 2011; Yang et al., 2011).  
 
We and others have previously demonstrated a key role of TSC1 in the 
establishment of naïve T-cell quiescence (O'Brien et al., 2011; Wu et al., 2011; Yang et 
al., 2011). Although the exit from quiescence in response to TCR stimulation is essential 
for proper T-cell activation and effector responses (Yang et al., 2013), how memory T 
cells reestablish a quiescent state is unclear. The increased cell size and dysregulated 
metabolic activities of Tsc1-deficient T cells are consistent with an impaired quiescence 
state of memory T cells. Additionally, gene expression profiling indicated that Tsc1-
deficient CD8+ T cells down-regulate the expression of transcription factors required for 
the maintenance of cell quiescence including Bach2 and KLF4 (Roychoudhuri et al., 
2013; Tsukumo et al., 2013; Yamada et al., 2009). Therefore, the failure to reestablish 
quiescence in Tsc1-deficient memory T cells is the likely basis for their poor recall 
responses to antigen rechallenge. This is reminiscent of the observation that abrogated 
quiescence of naïve T cells is associated with the defective initiation of primary immune 
responses (Yang et al., 2011). 
 
In summary, TSC1 functions as a critical controller of the generation and function 
of memory T cells. TSC1 regulates the formation of memory T cells through shaping the 
fate decisions between MPECs and SLECs and by orchestrating the transcriptional and 
metabolic programs. Modulation of TSC1 functions in T cells represents a potential 
strategy to enhance the quantity and quality of memory T cells against infections and 
tumors. 
 
 
Experimental Procedures 
 
 
Mice 
 
Tsc1fl/fl, CD45.1 and T-cell receptor-transgenic OT-1 mice were purchased from 
the Jackson Laboratory. Rosa26-Cre-ERT2 (CreER) mice have been described previously 
(Yang et al., 2011). GzmB-Cre mice were kindly provided by Drs. J. Jacob and M. Li. All 
mice were backcrossed to the C57BL/6 background for at least 8 generations. Animal 
protocols were approved by the Institutional Animal Care and Use Committee of St. Jude 
Children’s Research Hospital. 
 
 
Listeria monocytogenes infection 
 
For the study of primary immune response, mice were intravenously infected with 
3 × 104 colony-forming units (CFU) of LM-OVA. For the analysis of secondary immune 
response, mice were rechallenged with 5 × 104 CFU of LM-OVA at day 35 or more after 
primary infection. The recall responses were determined 4-6 days after the secondary 
infection. 
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Flow cytometry 
 
For analysis of surface markers, cells were stained in PBS containing 2% (wt/vol) 
BSA, with anti-CD4 (RM4-5), anti-CD8α (53-6.7), anti-TCRβ (H57-597), anti-CD44 
(1M7), anti-CD62L (MEL-14), anti-KLRG1 (2F1), anti-CD127 (A7R34), anti-CD45.1 
(A20), anti-CD45.2 (104), anti-CD244.2 (eBio244F4) (eBioscience) and Tim-3 (215008) 
(R&D Systems). OVA peptide (SIINFEKL)-loaded mouse H-2Kb tetramer was from 
Baylor Tetramer Production Facility. BrdU labeling and active caspase-3 staining were 
performed according to the manufacturer’s instructions (BD Biosciences). For 
intracellular staining, anti-Eomes (Dan11mag) and anti-Ki-67 (20Raj1) were purchased 
from eBioscience, anti-T-bet (4B10) and anti-Gzmb (GB11) from Biolegend, anti-Bcl2 
(N46-467) from BD Biosciences, and anti-Blimp-1 (3H2-E8) from Thermo Scientific. 
For intracellular cytokine staining, CD8+ T cells were stimulated for 5 hours with 
OVA257–264 (SIINFEKL) in the presence of monensin before being stained according 
to the manufacturer's instructions (BD Biosciences). ROS production was measured by 
incubating T cells for 30 min at 37°C with 10 μM CM-H2DCFDA (5-(and-6)-
chloromethyl-2,7-dichlorodihydrofluorescein diacetate acetyl ester; Invitrogen) after 
staining of surface markers. Staining with antibodies to S6 phosphorylated at Ser235 and 
Ser236 (D57.2.2E; Cell Signaling Technology) was done after fixing cells with Phospho 
Lyse/Fix Buffer, followed by permeabilization with Phosflow Perm Buffer III (BD 
Biosciences). Flow cytometry data were acquired on an LSRII or LSR Fortessa (BD 
Biosciences) and analyzed with FlowJo software (TreeStar). 
 
 
Cell purification and culture 
 
Sorted naïve T cells (CD8+CD62LhiCD44lo) from OT-1+ Tsc1+/+ CreER+ and OT-
1+ Tsc1fl/fl CreER+ mice were cultured in vitro in Click's medium (plus β-
mercaptoethanol) supplemented with 10% (vol/vol) FBS and 1% (vol/vol) penicillin-
streptomycin and stimulated with 10 μg/ml SIINFEKL peptide and 100 U/ml IL-2 for 4 
days in the presence of 0.5 μM 4-OHT. Ficoll-purified live CD8+ T cells were then 
stimulated with IL-15 (50 ng/ml) or IL-2 (50 U/ml) in the presence or absence of 
rapamycin (50 nM).  
 
 
Cell isolation and adoptive transfer 
 
For adoptive transfer, naïve CD8+ T cells from OT-I+ (CD45.2+) and Tsc1−/− OT-
I+ (CD45.1.2+) were transferred to CD45.1+ recipients. One day after transfer, mice were 
infected with 3 × 104 cfu of LM–OVA for the primary response and 5 × 104 CFU of LM–
OVA for the recall response. OVA+ CD8+ T cells were sorted from the spleen of WT or 
Tsc1−/− mice (CD45.2+) at day 41 p.i. and transferred into congenically marked 
(CD45.1+) recipients. One day after the transfer, mice were infected with 5 × 104 CFU of 
LM–OVA and used for the analysis of secondary CD8+ T-cell responses at days 4–6. 
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Metabolic assay 
 
The bioenergetic activities of the extracellular acidification rate and oxygen 
consumption rate pathways were measured using the Seahorse XF24-3 Extracellular Flux 
Analyzer per the manufacturer’s instructions (Seahorse Bioscience). The glycolytic flux 
assay was determined by measuring the detritiation of [3-3 H]-glucose, as described (Shi 
et al., 2011). 
 
 
Gene expression profiling by microarray analysis 
 
RNA samples from freshly isolated OVA+ CD8+ cells from WT (n = 4 after the 
exclusion of one sample due to abnormal Gapdh 3'/5' ratio and based on principal 
component analysis) and Tsc1−/− mice (n = 5) were analyzed with the Affymetrix HT 
MG-430 PM GeneTitan peg array, and expression signals were summarized with the 
robust multi-array average algorithm (Affymetrix Expression Console v1.1). Lists of 
differentially expressed genes by ANOVA (FDR < 0.1) were analyzed for functional 
enrichment using the Ingenuity Pathways (www.ingenuity.com). GSEA within canonical 
pathways was performed as described (Subramanian et al., 2005). 
 
 
RNA, genomic DNA, and immunoblot analyses  
 
Real-time PCR analysis was performed with primers and probe sets from Applied 
Biosystems, as described (Liu et al., 2009). Genomic DNA (gDNA) was purified from 
the sorted naïve CD8+ (CD8+CD62LhiCD44lo) T cells using a DNeasy blood and tissue 
kit from Qiagen. Tsc1 gDNA was quantified by real-time PCR normalizing with nuclear 
intron of β-globin gDNA with the following primers: Tsc1 forward 5′-
GTCACGACCGTAGGAGAAGC-3′, Tsc1 reverse 5′-GAATCAACCCCACAGAGCAT-
3′, and β-globin forward 5′-GAAGCGATTCTAGGGAGCAG-3′, β-globin reverse 5′-
GGAGCAGCGATTCTGAGTAGA-3′. Immunoblots were performed as described 
previously (Liu et al., 2010), using the following antibodies: p-S6 (2F9; Cell Signaling 
Technology) and β-actin (AC-15; Sigma). 
 
 
Statistical analysis 
 
P values were calculated with Student’s t-test (GraphPad Prism). P values of less 
than 0.05 were considered significant. All error bars represent the SEM. 
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